Inhibitors of human immunodeficiency virus replication

Abstract

Formula Ia, Formula Ib, Formula Ic or Formula Id: [Formula 1] Pharmaceutical compositions comprising the compound of TIFF2023521460000056.tif147170 or a pharmaceutically acceptable salt thereof are described.

Description

[Technical Field]

[0001] The present invention relates to pharmaceutical compositions and methods for using these compositions in the treatment of HIV infection. [Background technology]

[0002] Acquired immunodeficiency syndrome (AIDS) is the result of infection with HIV. HIV remains a major global public health problem. In 2015, an estimated 36.7 million people were living with HIV (including 1.8 million children), giving a global HIV prevalence of 0.8%. The majority of this number live in low- and middle-income countries. In the same year, 1.1 million people died from AIDS-related illnesses.

[0003] Current therapy for HIV-infected individuals consists of a combination of approved antiretroviral drugs. Nearly four dozen drugs are currently approved for HIV infection, either as single agents, fixed-dose combinations, or single-pill regimens (the latter two categories include two to four approved drugs). These drugs belong to several different classes, targeting either viral enzymes or the function of viral proteins during the viral replication cycle. Accordingly, drugs are classified as either nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), or entry inhibitors (one of which, maraviroc, targets the host CCR5 protein, while another, enfuvirtide, is a peptide that targets the gp41 region of the viral gp160 protein). In addition, pharmacokinetic enhancers (cobicistat or ritonavir) can be used in combination with antiretrovirals (ARVs) that require boosting.

[0004] Despite the medical armamentarium of drugs and drug combinations, there remains a medical need for new antiretroviral drugs. High viral heterogeneity, drug-related toxicity, tolerability issues, and poor adherence can all lead to treatment failure and may result in the selection of viruses with mutations that confer resistance to one or more antiretroviral agents from across classes, or even multiple drugs (Beyrer, C., Pozniak A. HIV drug resistance - an emerging threat to epidemic control. N. Engl. J. Med. 2017, 377, 1605-1607; Gupta, RK, Gregson J., et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect. Dis. 2017, 18, 346-355; Zazzi, M., Hu, H., Prosperi, M. The global burden of HIV-1 drug resistance in the past 20 years. PeerJ. 2018, DOI 10.7717 / peerj.4848). As a result, new drugs are needed that are easier to take, have a high genetic barrier to the development of resistance, and offer improved safety compared to current agents. In this plethora of options, novel mechanisms of action (MOAs) that could be used as part of the preferred antiretroviral therapy (ART) may still have a major role to play, as they should be effective against viruses resistant to current drugs.

[0005] Compounds with particular therapeutic potential have now been described in the art, including Blair, Wade S. et al. Antimicrobial Agents and Chemotherapy (2009), 53(12), 5080-5087, Blair, Wade S. et al. PLoS Pathogens (2010), 6(12), e1001220, Thenin-Houssier, Suzie; Valente, Susana T. Current HIV Research, 2016, 14, 270-282 and the following PCT patent applications: WO2012065062, WO2013006738, WO2013006792, WO2014110296, WO2014110297, WO2014110298, WO2014134566, WO2015130964, WO2015130966, WO2016033243, WO2018035359, WO2018203235, WO2019161017 and WO2019161280.

[0006] What is currently needed in the art are new compounds and further compounds that are useful in the treatment of HIV.In addition, these compounds should provide advantages for pharmaceutical use, for example, in terms of one or more of their mechanism of action, binding, inhibitory potency, target selectivity, solubility, safety profile, bioavailability and / or reduced administration frequency.New formulations and treatment methods utilizing these compounds are also needed.Formulations of certain compounds are disclosed in WO2020 / 018459. Summary of the Invention

[0007] Briefly, in one aspect, the present invention provides a compound of formula Ia, Ib, Ic, or Id: [ka] or a pharmaceutically acceptable salt thereof, and a solvent or diluent selected from the group consisting of water, alcohol, polyethylene glycol (PEG), N-methyl-2-pyrrolidone (NMP), ethyl lactate, propylene glycol, glycofurol, and dimethyl sulfoxide (DMSO).

[0008] In another embodiment, the present invention discloses a method for treating HIV infection in a human comprising administering a compound or salt of the present invention.

[0009] In another aspect, the present invention discloses a compound or salt of the present invention for use in therapy.

[0010] In another aspect, the present invention discloses a compound or salt of the present invention for use in the treatment of HIV infection in a human.

[0011] In another embodiment, the present invention discloses the use of a compound or salt of the present invention in the manufacture of a medicament for the treatment of HIV infection in a human. [Brief explanation of the drawings]

[0012] [Figure 1] FIG. 1 shows an outline of the PK experiment described below. DETAILED DESCRIPTION OF THE INVENTION

[0013] In one embodiment, the pharmaceutical composition of the present invention further comprises an excipient selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, poloxamer 207, poloxamer 338, sodium chloride, and sodium hydroxide.

[0014] In one embodiment, the pharmaceutical composition of the invention is a solution.

[0015] In one embodiment, the pharmaceutical composition of the invention is a suspension.

[0016] In one embodiment, the pharmaceutical composition of the present invention comprises water.

[0017] In one embodiment, the pharmaceutical composition of the invention comprises polyethylene glycol (PEG).

[0018] In one embodiment, the pharmaceutical composition of the present invention comprises polyethylene glycol (PEG), wherein the PEG has an average molecular weight of about 300 (PEG300).

[0019] In one embodiment, the pharmaceutical composition of the present invention comprises ethanol.

[0020] In one embodiment, the pharmaceutical composition of the present invention comprises ethyl lactate.

[0021] In one embodiment, the pharmaceutical composition of the present invention comprises poloxamer 188.

[0022] In one embodiment, the pharmaceutical composition of the present invention comprises sodium hydroxide.

[0023] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition in which at least 90% by weight of the solvent or diluent is water and PEG300.

[0024] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition in which at least 90% by weight of the excipient is poloxamer 188.

[0025] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition in which water is present in an amount of 8 to 20% by weight in the composition and PEG300 is present in an amount of 60 to 85% by weight in the composition.

[0026] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition in which water is present in an amount of 8 to 12% by weight in the composition and PEG300 is present in an amount of 63 to 70% by weight in the composition.

[0027] In one embodiment, the pharmaceutical composition of the present invention is a pharmaceutical composition in which the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is present in the composition at a concentration of 50 to 500 mg / mL, based on the weight of the free compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id. Throughout this specification, references to the concentration of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, always refer to the concentration based on the free compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, and not the concentration based on a salt thereof.

[0028] In one aspect, the pharmaceutical composition of the present invention is a pharmaceutical composition in which the compound of formula Ia, formula Ib, formula Ic, or formula Id or a pharmaceutically acceptable salt thereof is present in the composition at a concentration of 225 to 275 mg / mL.

[0029] In one aspect, the pharmaceutical composition of the present invention is a pharmaceutical composition in which the compound of formula Ia, formula Ib, formula Ic, or formula Id or a pharmaceutically acceptable salt thereof is present in the composition at a concentration of 275 to 350 mg / mL.

[0030] In one aspect, the pharmaceutical composition of the present invention is a pharmaceutical composition in which the compound of formula Ia, formula Ib, formula Ic, or formula Id or a pharmaceutically acceptable salt thereof is present in the composition at a concentration of 350 to 425 mg / mL.

[0031] In one embodiment, the pharmaceutical composition of the invention is made from a crystalline form of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the invention is a suspension of a crystalline form of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof.

[0032] In one embodiment, the pharmaceutical composition of the present invention is made from an amorphous form of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the amorphous form is a lyophilized powder. In another embodiment, the pharmaceutical composition of the present invention is a suspension of the amorphous form.

[0033] In another embodiment, the formulation comprises water. In another embodiment, the formulation comprises glycofurol. In another embodiment, the formulation comprises N-methyl-2-pyrrolidone (NMP). In another embodiment, the formulation comprises dimethyl sulfoxide (DMSO). In another embodiment, the formulation comprises alcohol. In another embodiment, the formulation comprises ethanol. In another embodiment, the formulation comprises saline. In another embodiment, the formulation comprises polyethylene glycol (PEG), whose chemical formula is generally H—(O—CH2—CH2) n In another embodiment, the formulation comprises PEG having an average molecular weight of about 100 (PEG100). In another embodiment, the formulation comprises PEG having an average molecular weight of about 200 (PEG200). In another embodiment, the formulation comprises PEG having an average molecular weight of about 300 (PEG300). In another embodiment, the formulation comprises PEG having an average molecular weight of about 400 (PEG400). In another embodiment, the formulation comprises PEG having an average molecular weight of about 500 (PEG500). In another embodiment, the formulation comprises PEG having an average molecular weight of about 600 (PEG600). In another embodiment, the formulation comprises PEG "capped" with an alkyl group, such that the formula of PEG is generally alkyl-(O-CH2-CH2). n -O-alkyl. In another embodiment, the formulation comprises more than 50 w / w% of ingredients other than water. In another embodiment, the formulation comprises more than 60 w / w% of ingredients other than water. In another embodiment, the formulation comprises more than 70 w / w% of ingredients other than water. In another embodiment, the formulation comprises more than 80 w / w% of ingredients other than water. In another embodiment, the formulation comprises more than 85 w / w% of ingredients other than water. In another embodiment, the formulation comprises more than 90 w / w% of ingredients other than water. In another embodiment, the formulation comprises water and PEG200. In another embodiment, the formulation comprises water and PEG300.

[0034] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, and a solubilizing additive. In another embodiment, the solubilizing additive is a polysorbate. In another embodiment, the solubilizing additive is polysorbate 20. In another embodiment, the solubilizing additive is polysorbate 80. In another embodiment, the solubilizing additive is a poloxamer. In another embodiment, the solubilizing additive is poloxamer 188 (P188). In another embodiment, the solubilizing additive is poloxamer 207. In another embodiment, the solubilizing additive is poloxamer 338 (P338). In another embodiment, the solubilizing additive is docusate sodium. In another embodiment, the solubilizing additive is polyethylene glycol 3350 (PEG3350). In another embodiment, the solubilizing additive is a fatty acid. In another embodiment, the solubilizing additive is a fatty acid containing 8 to 12 carbon atoms. In another embodiment, the solubilizing additive is a fatty acid containing 8 carbons (C8). In another embodiment, the solubilizing additive is a fatty acid containing 12 carbons (C12). In another embodiment, the solubilizing additive is less than 5 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 5 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 4 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 3 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 2 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 1 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 0.5 w / w% of the formulation. In another embodiment, the solubilizing additive is less than about 0.25 w / w% of the formulation.

[0035] In one embodiment, the pharmaceutical composition of the invention comprises poloxamer 188 and a C8 fatty acid. In another embodiment, the ratio of poloxamer 188 to C8 fatty acid is about 3:1. In another embodiment, the concentration of poloxamer 188 is about 3 wt% of the formulation and the concentration of C8 fatty acid is about 1 wt% of the formulation.

[0036] In one embodiment, the pharmaceutical composition of the invention comprises poloxamer 188 and a C12 fatty acid. In another embodiment, the ratio of poloxamer 188 to C12 fatty acid is about 6:1. In another embodiment, the concentration of poloxamer 188 is about 3 wt% of the formulation and the concentration of C12 fatty acid is about 0.5 wt% of the formulation.

[0037] In one embodiment, the pharmaceutical composition of the invention comprises poloxamer 338 and a C8 fatty acid. In another embodiment, the ratio of poloxamer 338 to C8 fatty acid is about 3:1. In another embodiment, the concentration of poloxamer 338 is about 3 wt% of the formulation and the concentration of C8 fatty acid is about 1 wt% of the formulation.

[0038] In one embodiment, the pharmaceutical composition of the invention comprises poloxamer 338 and a C12 fatty acid. In another embodiment, the ratio of poloxamer 338 to C12 fatty acid is about 6:1. In another embodiment, the concentration of poloxamer 338 is about 3 wt% of the formulation and the concentration of C12 fatty acid is about 0.5 wt% of the formulation.

[0039] In one embodiment, the pharmaceutical composition of the present invention comprises docusate sodium and a C8 fatty acid. In another embodiment, the ratio of docusate sodium to C8 fatty acid is about 3:1. In another embodiment, the concentration of docusate sodium is about 3 wt% of the formulation and the concentration of C8 fatty acid is about 1 wt% of the formulation.

[0040] In one embodiment, the pharmaceutical composition of the present invention comprises docusate sodium and a C12 fatty acid. In another embodiment, the ratio of docusate sodium to C12 fatty acid is about 6:1. In another embodiment, the concentration of docusate sodium is about 3 wt% of the formulation and the concentration of C12 fatty acid is about 0.5 wt% of the formulation.

[0041] In one embodiment, the pharmaceutical composition of the present invention comprises a chelating agent. In another embodiment, the chelating agent is Na-EDTA. In another embodiment, the Na-EDTA is present at 0.01-0.05 w / w% of the formulation.

[0042] In one embodiment, the pharmaceutical composition of the present invention comprises an antioxidant. In another embodiment, the antioxidant is L-methionine. In another embodiment, the antioxidant is vitamin E. In another embodiment, the antioxidant is present at 0.01-0.10 w / w% of the formulation.

[0043] In one embodiment, the pharmaceutical composition of the present invention comprises an acid. In another embodiment, the acid is ethanesulfonic acid. In another embodiment, the concentration of the ethanesulfonic acid is 1 to 10 mM. In another embodiment, the concentration of the ethanesulfonic acid is 4.8 to 5.2 mM. In another embodiment, the acid is methanesulfonic acid. In another embodiment, the concentration of the methanesulfonic acid is 1 to 10 mM. In another embodiment, the concentration of the methanesulfonic acid is 4.8 to 5.2 mM.

[0044] In one embodiment, the pharmaceutical composition of the present invention comprises a base. In another embodiment, the base is an inorganic base. In another embodiment, the base is an organic base. In another embodiment, the anion of the base is - OH (hydroxide). In another embodiment, the anion of the base is - OEt (ethoxide). In another embodiment, the anion of the base is - In another embodiment, the cation of the base is + In another embodiment, the cation of the base is +In another embodiment, the base is K (potassium). In another embodiment, the cation of the base is choline. In another embodiment, the base is sodium acetate. In another embodiment, the base is sodium hydroxide. In another embodiment, the base is sodium ethoxide. In another embodiment, the base is choline hydroxide. In another embodiment, the pharmaceutical composition of the present invention comprises 0.1 to 1.5 molar equivalents of the base relative to the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id. In another embodiment, the pharmaceutical composition of the present invention comprises 0.7 to 1.2 molar equivalents of the base relative to the compound of Formula Ia or Formula Ib. In another embodiment, the pharmaceutical composition of the present invention comprises 0.7 to 1.0 molar equivalents of the base relative to the compound of Formula Ia or Formula Ib. In another embodiment, the pharmaceutical composition of the present invention comprises 1.0 to 1.2 molar equivalents of the base relative to the compound of Formula Ia or Formula Ib. In another embodiment, the pharmaceutical composition of the present invention comprises approximately equimolar equivalents of the base and the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id.

[0045] In one embodiment, the pharmaceutical composition of the present invention comprises a buffer solution. In another embodiment, the buffer solution is an acetate buffer solution. In another embodiment, the pH of the buffer solution is 4.0 to 7.4. In another embodiment, the pH of the buffer solution is 4.0 to 5.5. In another embodiment, the pH of the buffer solution is 4.8 to 5.2. In another embodiment, the concentration of the buffer solution is 1 to 10 mM. In another embodiment, the concentration of the buffer solution is 4.8 to 5.2 mM.

[0046] In one embodiment, the pharmaceutical composition of the present invention contains 50-500 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention contains about 50 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention contains about 100 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention contains about 150 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention contains about 200 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention comprises about 250 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention comprises about 300 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention comprises about 350 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention comprises about 400 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention comprises about 450 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof. In another embodiment, the pharmaceutical composition of the present invention comprises about 500 mg / mL of a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof.

[0047] In one embodiment, the pharmaceutical composition of the invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof, water, PEG300, and 0 to 3 additional excipients.

[0048] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof, water, PEG200, and 0 to 3 additional excipients.

[0049] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof, poloxamer P338, and an acetate buffer. In another embodiment, the concentration of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof is 280 to 320 mg / mL. In another embodiment, the concentration of poloxamer P338 is 3 to 5 w / w%. In another embodiment, the pH of the acetate buffer is 4.8 to 5.2. In another embodiment, the concentration of the acetate buffer is 4.8 to 5.2 mM.

[0050] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof, poloxamer P338, ethanesulfonic acid, and an acetate buffer. In another embodiment, the concentration of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof is 280 to 320 mg / mL. In another embodiment, the concentration of poloxamer P338 is 3 to 5 w / w%. In another embodiment, the concentration of ethanesulfonic acid is 4.8 to 5.2 mM. In another embodiment, the pH of the acetate buffer is 4.8 to 5.2. In another embodiment, the concentration of the acetate buffer is 4.8 to 5.2 mM.

[0051] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof, poloxamer P338, a C8-C12 fatty acid, and an acetate buffer. In another embodiment, the concentration of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof is 280-320 mg / mL. In another embodiment, the concentration of poloxamer P338 is 3-5 w / w%. In another embodiment, the concentration of the fatty acid is 0.5-1 w / w%. In another embodiment, the pH of the acetate buffer is 4.8-5.2. In another embodiment, the concentration of the acetate buffer is 4.8-5.2 mM.

[0052] In one embodiment, the pharmaceutical composition of the present invention comprises a compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof, docusate sodium, and an acetate buffer. In another embodiment, the concentration of the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id or a pharmaceutically acceptable salt thereof is 280 to 320 mg / mL. In another embodiment, the concentration of docusate sodium is 1 to 2 w / w%. In another embodiment, the pH of the acetate buffer is 4.8 to 5.2. In another embodiment, the concentration of the acetate buffer is 4.8 to 5.2 mM.

[0053] In one aspect, the present invention discloses a pharmaceutical composition, wherein the pharmaceutical composition is a solution and is sterilized by passing it through a filter.

[0054] The salts of the present invention are pharmaceutically acceptable. Such salts can be acid addition salts or base addition salts. For a review of suitable pharmaceutically acceptable salts, see, for example, Berge et al., J. Pharm. Sci., 66, 1-19, 1977.

[0055] Representative pharmaceutically acceptable acid addition salts include, but are not limited to, 4-acetamidobenzoate, acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate (besylate), benzoate, bisulfate, bitartrate, butyrate, calcium edetate, camphorate, camphorsulfonate (camsylate), caprate (decanoate), caproate (hexanoate), caprylate (octanoate), cinnamate, citrate, cyclamate, digluconate, and 2,5-dihydroxybenzoate. , disuccinate, dodecyl sulfate (estolate), edetate (ethylenediaminetetraacetate), estolate (lauryl sulfate), ethane-1,2-disulfonate (edisylate), ethanesulfonate (esylate), formate, fumarate, galactarate (mucate), gentisate (2,5-dihydroxybenzoate), glucoheptonate (gluceptate), gluconate, glucuronate, glutamate, glutarate, glycerophosphate, glycolate, hexylresorcinol, hippurate, hydrabamine (N, N'-di(dehydroabietyl)-ethylenediamine), hydrobromide, hydrochloride, hydroiodide, hydroxynaphthoate, isobutyrate, lactate, lactobionate, laurate, malate, maleate, malonate, mandelate, methanesulfonate (mesylate), methylsulfate, mucate, naphthalene-1,5-disulfonate (napadisylate), naphthalene-2-sulfonate (napsylate), nicotinate, nitrate, oleate, palmitate, p-aminobenzenesulfonate, p-aminosalicylate, paclitaxel These include molate (embonate), pantothenate, pectinate, persulfate, phenylacetate, phenylethylbarbiturate, phosphate, polygalacturonate, propionate, p-toluenesulfonate (tosylate), pyroglutamate, pyruvate, salicylate, sebacate, stearate, subacetate, succinate, sulfamate, sulfate, tannate, tartrate, teoclate (8-chlorotheophyllinate), thiocyanate, triethiodide, undecanoate, undecylenate, and valerate.

[0056] Representative pharmaceutically acceptable base addition salts include, but are not limited to, aluminum, 2-amino-2-(hydroxymethyl)-1,3-propanediol (TRIS, tromethamine), arginine, benethamine (N-benzylphenethylamine), benzathine (N,N'-dibenzylethylenediamine), bis-(2-hydroxyethyl)amine, bismuth, calcium, chloroprocaine, choline, clemizole (1-p-chlorobenzyl-2-pyrrolizin-1'-ylmethylbenzylamine), and benzophenone (benzophenone). dibenzoimidazole), cyclohexylamine, dibenzylethylenediamine, diethylamine, diethyltriamine, dimethylamine, dimethylethanolamine, dopamine, ethanolamine, ethylenediamine, L-histidine, iron, isoquinoline, lepidine, lithium, lysine, magnesium, meglumine (N-methylglucamine), piperazine, piperidine, potassium, procaine, quinine, quinoline, sodium, strontium, t-butylamine, and zinc.

[0057] A particularly preferred salt is the sodium salt. Another particularly preferred salt is the potassium salt.

[0058] In one embodiment, the composition of the present invention further comprises a pharmaceutically acceptable additive. In the method of the present invention, the preferred administration route is oral administration and injection administration for subcutaneous or intramuscular delivery. Therefore, preferred pharmaceutical compositions include compositions suitable for oral administration (e.g., tablets) and compositions suitable for subcutaneous or intramuscular injection.

[0059] In another aspect, the present invention discloses a method for preventing or reducing the risk of HIV infection in humans, comprising administering a pharmaceutical composition of the present invention. Pre-exposure prophylaxis (or PrEP) is when people at risk of HIV infection take medication daily to reduce the chance of HIV infection. PrEP has been shown to be effective in reducing the risk of infection.

[0060] The compounds and salts of the present invention are believed to have the HIV capsid as their biological target, and therefore their mechanism of action is to alter the function of the HIV capsid in one or more ways.

[0061] The compounds and salts of the present invention can be used alone or in combination with other therapeutic agents. Thus, combination therapy according to the present invention comprises the administration of at least one compound or salt of the present invention and at least one other agent that may be useful in the treatment of HIV infection. The compound or salt of the present invention and the other agent may be formulated and administered together in a single pharmaceutical composition, or may be formulated and administered separately. When formulated and administered separately, they may be administered simultaneously or sequentially in any order. Suitable other drugs include, for example, abacavir, atazanavir, bictegravir, cabotegravir, darunavir, delavirdine, didanosine, dideoxyinosine, dolutegravir, doravirine, efavirenz, elvitegravir, emtricitabine, etavirine, fosamprenavir, fostemsavir, indinavir, slatravir, lamivudine, lopinavir, maraviroc, nelfinavir, nevirapine, raltegravir, rilpiverine, ritonavir, saquinavir, stavudine, tipranavir, tenofovir, tenofovir alafenamide, tenofovir disoproxil fumarate, zalcitabine, and zidovudine. Preferred drugs include, for example, islatravir, lamivudine, fostemsavir, and cabotegravir. Particularly preferred agents include, for example, dolutegravir, bictegravir, lamivudine, fostemsavir, and cabotegravir. [Example]

[0062] Preparation of bicyclo[3.1.0]hexan-3-ol

[0063] [ka]

[0064] To a stirred solution of cyclopent-3-enol (130 g, 1545 mmol) in DCM under a N2 atmosphere at 0–5 °C, a solution of diethylzinc in hexanes (1.0 M, 3091 mL, 3091 mmol) was added dropwise over 3 h. At 0 °C, a solution of diiodomethane (249 mL, 3091 mmol) in DCM (300 mL) was added dropwise over 1 h. The reaction mixture was warmed to 27 °C, and the formation of a white precipitate was observed. The mixture was stirred for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% EtOAc / PET, Rf = 0.3, UV-inactive, PMA-active). The reaction mixture was quenched by the careful addition of saturated aqueous NH4Cl (1.5 L). The mixture was filtered through a pad of Celite. The aqueous layer was extracted with DCM (2 × 1 L). The combined organic layers were dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure to give crude bicyclo[3.1.0]hexan-3-ol as a red liquid (180 g). 1 H NMR (400 MHz, CDCl3) δ = 4.41 - 4.35 (m, 1H), 2.18 - 2.05 (m, 2H), 1.73 (d, J = 13.9 Hz, 2H), 1.35 - 1.25 (m, 2H), 1.21 - 1.14 (m, 1H), 0.57 - 0.43 (m, 2H). GCMS: m / z = 98.1).

[0065] Preparation of bicyclo[3.1.0]hexan-3-one

[0066] [ka]

[0067] To a stirred solution of bicyclo[3.1.0]hexan-3-ol (210 g, 2054 mmol) in DCM (5000 mL) under a N atmosphere at 0 °C, Dess-Martin periodinane (954 g, 225 mmol) was added portionwise. The mixture was warmed to 27 °C and then stirred for 16 h. The reaction progress was monitored by TLC (SiO, 20% acetone / Hex, Rf = 0.3, UV inactive, PMA active). The reaction mixture was filtered through a Celite pad, and the filtrate was washed with aqueous NaOH (1 N, 8 × 1 L). The combined aqueous phase was extracted with DCM (5 × 1 L). The combined organic layers were dried over anhydrous NaSO, filtered, and then concentrated under reduced pressure (bath temperature: 20 °C) to give crude bicyclo[3.1.0]hexan-3-one as a brown liquid. The liquid was further purified by downward distillation at 70° C. to give bicyclo[3.1.0]hexan-3-one as a pale yellow viscous liquid (125 g, 62%). 1 GCMS: M / Z = 96.1.

[0068] Preparation of 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one

[0069] [ka]

[0070] To a stirred solution of bicyclo[3.1.0]hexan-3-one (125 g, 1274 mmol) in THF (1500 mL) was added LDA (2.0 M in THF, 0.701 L, 1402 mmol) under a N atmosphere at −78 °C. The solution was stirred at −78 °C for 1 h. To the solution was slowly added a solution of ethyl difluoroacetate (174 g, 1402 mmol) in THF (300 mL) over 30 min, maintaining the temperature at −78 °C. The reaction mixture was warmed to 27 °C and then stirred for 1 h. The progress of the reaction was monitored by TLC (SiO, 20% acetone / hexane, Rf = 0.3, UV active). The reaction mixture was quenched by the addition of aqueous HCl (1 N, 2000 mL). The mixture was stirred for 30 min and then extracted with EtOAc (3 × 1000 mL). The combined organic layers were washed with brine (1000 mL), dried over anhydrous NaSO, and filtered. The filtrate was concentrated under reduced pressure to give 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one as a pale yellow viscous liquid (180 g, 71%). 1 H NMR (400 MHz, CDCl3) δ = 6.18 (t, J = 54.8 Hz, 1H), 2.70 - 2.62 (m, 1H), 2.35 (d, J = 19.4 Hz, 1H), 2.14 (br s, 1H), 1.26 - 1.21 (m, 1H), 1.04-1.03 (m, 1H), 0.22-0.21 (m, 1H), LCMS: M / Z = 173.17).

[0071] Preparation of ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate

[0072] [ka]

[0073] To a stirred solution of 2-(2,2-difluoroacetyl)bicyclo[3.1.0]hexan-3-one (180 g, 910 mmol) in ethanol (2 L) at 27 °C under a N atmosphere, ethyl 2-hydrazinyl acetate hydrochloride (422 g, 2729 mmol) was added, followed by sulfuric acid (20 mL, 375 mmol). The mixture was stirred for 30 min, then heated to 100 °C and stirred for 16 h. The progress of the reaction was monitored by TLC (SiO, 20% acetone / hexane, Rf = 0.3, UV-active). The reaction mixture was concentrated under reduced pressure. The residue was dissolved in EtOAc (2000 mL), washed with water (2 × 1 L), brine (1.0 L), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure. The resulting residue was subjected to silica gel column chromatography (pet.:acetone 100:0→98:2) to give ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate as an off-white solid (110 g, 46%). 1 H NMR (400 MHz, DMSO-d6) δ = 6.86 (t, J = 54.8 Hz, 1H), 4.93 (s, 2H), 4.14 (q, J = 7.2 Hz, 2H), 2.88 - 2.79 (m, 1H), 2.76 - 2.68 (m, 1H), 2.14 - 2.04 (m, 2H), 1.19 (t, J = 7.2 Hz, 3H), 1.10 - 1.03 (m, 1H), 0.14 (q, J = 4.3 Hz, 1H).

[0074] Preparation of ethyl 2-(3-(difluoromethyl)-5-oxo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate

[0075] [ka]

[0076] To a stirred solution of ethyl 2-(3-(difluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (110 g, 422 mmol) and Celite (395 g) in cyclohexane (3.5 L) was added pyridinium dichromate (794 g, 2110 mmol) in portions at 0 °C. Under a nitrogen atmosphere, tert-butyl hydroperoxide (355 mL, 2130 mmol) was added dropwise over 10 min. The reaction mixture was warmed to 27 °C and then stirred at that temperature for 48 h. The progress of the reaction was monitored by TLC (SiO, 30% acetone / PET, Rf = 0.4, UV active). The reaction mixture was filtered, and the filter cake was extracted with EtOAc (1000 mL). The filtrate was washed with saturated aqueous NaSO (2 x 500 mL), saturated aqueous FeSO (300 mL), and then brine (500 mL). The organic layer was dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give the crude title compound (150 g).

[0077] Preparation of ethyl 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2'-[1,3]dithiolane]-1(3bH)-yl)acetate

[0078] [ka]

[0079] To a stirred solution of ethyl 2-(3-(difluoromethyl)-5-oxo-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (75 g, 269 mmol) in DCM (1500 mL) under a nitrogen atmosphere at 27 °C, ethane-1,2-dithiol (43.0 mL, 511 mmol) was added, followed by boron trifluoride acetic acid (72.6 mL, 511 mmol). The solution was stirred for 16 h. The progress of the reaction was monitored by TLC (SiO, 20% acetone / Pet, Rf = 0.35, UV active). Upon completion, the reaction mixture was cooled to 0 °C and quenched by the addition of saturated aqueous NaHCO (500 mL). The mixture was extracted with DCM (2 × 1000 mL). The combined organics were washed with brine (1000 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a brown liquid, which was subjected to silica gel column chromatography (Pet.: EtOAc 95:5 to 90:10) to give ethyl 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2'-[1,3]dithiolane]-1(3bH)-yl)acetate as an off-white solid (80 g, 74%). 1 H-NMR (400 MHz, CDCl3) δ = 6.61 (t, J = 55.2 Hz, 1H), 5.00 - 4.85 (m, 2H), 4.29 - 4.19 (m, 2H), 3.55 - 3.46 (m, 4H), 2.63 - 2.53 (m, 1H), 2.49 - 2.38 (m, 1H), 1.30 - 1.24 (m, 4H), 0.65 - 0.60 (m, 1H). LCMS M+H = 346.9.

[0080] Preparation of ethyl 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate

[0081] [ka]

[0082] To a stirred solution of 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (26.3 g, 92 mmol) in DCM (20 mL) was added HF-pyridine (2.460 g, 24.83 mmol) under a N atmosphere at -70 °C. The solution was stirred for 30 min. To the solution was added a solution of ethyl 2-(3-(difluoromethyl)-4,4a-dihydrospiro[cyclopropa[3,4]cyclopenta[1,2-c]pyrazole-5,2'-1,3]dithiolane]-1(3bH)-yl)acetate (10 g, 25 mmol) in DCM (20 mL). The reaction mixture was warmed to -40 °C and then stirred at that temperature for 1 h. The progress of the reaction was monitored by TLC (SiO, 30% EtOAc / Pet, Rf = 0.3, UV inactive). The reaction mixture was quenched by the addition of saturated aqueous NaHCO (200 mL). The mixture was warmed to room temperature and then extracted with EtOAc (2 × 100 mL). The combined organics were washed with brine (50 mL), dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give a brown solid. This material was subjected to silica gel column chromatography (Pet.: EtOAc 100:0 → 75-25) to give ethyl 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate as a pale yellow solid (8.5 g, 91%). 1 H NMR (400 MHz, CDCl3) δ = 6.62 (t, J = 55.2 Hz, 1H), 4.82 (s, 2H), 4.30 - 4.18 (m, 2H), 2.51 - 2.37 (m, 2H), 1.42 - 1.35 (m, 1H), 1.31 - 1.23 (m, 3H), 1.14 - 1.08 (m, 1H). LCMS M+H = 293.07.

[0083] Preparation of 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid

[0084] [ka]

[0085] To a stirred solution of ethyl 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetate (15 g, 50 mmol) in THF (17 mL) and MeOH (66 mL) was added a solution of LiOH (1.788 g, 74.7 mmol) in water (66 mL) under a N atmosphere at 0 °C. The reaction mixture was warmed to 27 °C and then stirred at that temperature for 3 h. The reaction progress was monitored by TLC (SiO, 5% MeOH / DCM, Rf = 0.2, UV active). Upon completion, the reaction mixture was concentrated under reduced pressure, diluted with water (50 mL), and washed with EtOAc (2 × 250 mL) to remove impurities. The aqueous layer was adjusted to pH 2-3 using aqueous HCl (1 M) and then extracted with EtOAc (3 × 1000 mL). The combined organics were dried over anhydrous NaSO, filtered, and concentrated under reduced pressure to give 2-(3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid as an off-white solid (14 g, 98%). LCMS M+H = 265.15.

[0086] Separation of the resulting 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid and 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid

[0087] [ka]

[0088] 2-(3-(Difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (5.5 g) was dissolved in isopropanol (20 mL). The solution was subjected to SFC chiral separation in small portions as follows: Instrument: Thar 80; Column: Chiralpak IC 30 × 250 mm, 5 microns; Solvent A: supercritical CO ; Solvent B: 0.5% isopropylamine in isopropanol (v / v); Eluent composition: 70% A: 30% B; Flow rate: 65 g / min; Back pressure: 100 bar; Temperature: 30 °C; Injection volume: 2.5 mL; Detection: 220 nm. 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid was collected as a peak eluting between 7.5 and 14 min, and 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid was collected as a peak eluting between 2.7 and 5.8 min. For each enantiomer, the resulting solution was concentrated under reduced pressure, and the resulting solid was dissolved in EtOAc and then washed twice with aqueous citric acid (1 M), followed by water, followed by brine. The organic solution was dried over Na2SO4, filtered, and then concentrated in vacuo to give the separated enantiomers in 80-90% recovery.

[0089] Preparation of N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide

[0090] [ka]

[0091] Synthesis scheme

[0092] [ka]

[0093] Step 1: Preparation of 2,6-dichloro-3-nitrobenzaldehyde

[0094] [ka]

[0095] To a solution of sulfuric acid (H2SO4) (5.63 L, 4.5 V) in a round-bottom flask at 0-5 °C, 2,6-dichlorobenzaldehyde (1.25 kg, 7.10 mol, 1.0 equiv.) was added portionwise at <15 °C. The reaction was stirred at 0-5 °C for 30 min. A freshly prepared solution of nitration mixture [prepared from concentrated H2SO4 (0.425 L, 0.34 V) and 70% HNO3 (0.85 kg, 13.49 mol, 1.30 equiv.) at 0 °C] was added to the above reaction mixture at <10 °C. [Note: This is a slightly exothermic reaction (3-6 °C), so adding at a low temperature is preferred.] The reaction mixture was stirred at 5-10 °C for 2-3 h. After completion of the reaction (monitored by TLC), it was quenched with ice-cold water (18.75 L, 15 V) at <25 °C. The reaction was then warmed to room temperature and stirred for 2 hours. The solid was isolated by filtration and then washed with water (2.5 L, 2.0 V). Bulk residual water was removed from the solid by vacuum filtration for 60-90 minutes. The crude wet solid was first dried under air and then in a hot air oven at 50-55°C for 10-12 hours (until the water content was 5.0% or less) to give the title product, 2,6-dichloro-3-nitrobenzaldehyde (1.44 kg, 92% yield), as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 10. 44 (s, 1H), 7.88 (d, J = 8.4 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H).

[0096] Step 2: Preparation of 2,6-dichloro-3-nitrobenzonitrile

[0097] [ka]

[0098] (Process-2a) To a solution of DMSO (5.9 L, 5.0 V) in a round-bottom flask was added 2,6-dichloro-3-nitrobenzaldehyde (1.17 kg, 5.31 mol, 1.0 equiv.) at room temperature. After stirring for 30 min at room temperature, hydroxylamine hydrochloride (0.63 kg, 9.04 mol, 1.70 equiv.) was added, and the reaction was stirred at room temperature for 3 h. After completion of the reaction (monitored by TLC), the reaction was quenched by the addition of ice-cold water (18.0 L, 15.0 V) at a rate sufficient to maintain the temperature below 30 °C (observation: solid formed upon water addition). The reaction was stirred at room temperature for 60–90 min. The solid was isolated by filtration and washed with water (2.5 L, 2.0 V), followed by a mixture of acetone and hexane (6.0 L, 1:1 ratio). Bulk residual water was removed from the solid by maintaining vacuum filtration for 60–90 min. The wet solid was first air-dried and then finally dried in a hot air oven at 50-55°C for 10-12 hours (until the moisture content was 1.0% or less) to give the dried target product, 2,6-dichloro-3-nitrobenzaldehyde oxime (1.22 kg, 92% yield), as an off-white solid. The crude product (containing 10-20% 2,6-dichloro-3-nitrobenzonitrile) was used directly in the next step without further purification.

[0099] (Process-2b) To a stirred solution of crude oxime (prepared above, 1.13 kg, 4.80 mol, 1.0 equiv.) in DCM (9.04 L, 8.0 V) at 0–5 °C, triethylamine ("TEA", 1.02 kg, 10.09 mol, 2.1 equiv.) was added. After stirring for 5 min, methanesulfonyl chloride (0.60 kg, 5.29 mol, 1.1 equiv.) was added slowly at 15 °C (observation: an exotherm was observed during the addition). The reaction was then stirred at room temperature for 30–45 min. After completion of the reaction (reaction progress was monitored by TLC; mobile phase: 20% ethyl acetate in hexane), the reaction was diluted with water (6.78 L, 6.0 V), the organic layer was separated, and the aqueous layer was extracted with DCM (3.4 L, 3.0 V). The combined organic layers were washed with brine (5.65 L, 5.0 V), dried over Na2SO4, and concentrated in vacuo. The resulting crude solid was triturated with hexane (4.50 L, 4.0 V) at room temperature. The wet material was dried in a hot air oven at 50-55 °C for 5-6 hours to give the dried product, 2,6-dichloro-3-nitrobenzonitrile (0.95 kg, 91% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 8.07 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.8 Hz, 1H).

[0100] Step 3: Preparation of 4-chloro-7-nitro-1H-indazol-3-amine

[0101] [ka]

[0102] To a stirred solution of 2,6-dichloro-3-nitrobenzonitrile (750.0 g, 3.45 mol, 1.0 equiv.) in ethanol (7.5 L, 10.0 V) at 15–20 °C, hydrazine hydrate (519.0 g, 10.36 mol, 3.0 equiv.) was slowly added, maintaining the reaction temperature below 25 °C (observation: slight exotherm upon addition, solid formation begins upon addition). The temperature of the reaction mixture was slowly raised to room temperature, and the mixture was then stirred for 3 h (observation: the amount of solid increased during this time). After completion of the reaction (monitored by TLC), the mixture was diluted with water (7.5 L, 10.0 V) and further stirred at room temperature for 1 h. The solid was isolated by filtration and then washed with water (2.25 L, 3.0 V). The wet solid was washed with a 1:1 mixture of acetone (1.875 L, 2.5 V) and hexane (1.875 L, 2.5 V). Bulk residual water was removed from the solid by vacuum filtration for 60–90 min. Finally, the wet solid was dried in a hot air oven at 50 °C for 7–8 h (until the moisture content was less than 1.5%) to obtain the dried product, 4-chloro-7-nitro-1H-indazol-3-amine (549.0 g, 75% yield), as a brick-red solid. 1 H NMR (400 MHz, CDCl3): δ 10.36 (bs, 1H), 8.20 (d, J = 8.4 Hz, 1H), 7.07 (d, J = 8.40 Hz, 1H), 4.73 (bs, 2H).

[0103] Step 4: Preparation of 4-chloro-1-methyl-7-nitro-1H-indazol-3-amine

[0104] [ka]

[0105] To a stirred solution of 4-chloro-7-nitro-1H-indazol-3-amine (500 g, 0.42 mol, 1.0 equiv.) in DMF (5.0 L, 10.0 V) at 5–10 °C, cesium carbonate (CsCO) (1.91 kg, 5.88 mol, 2.5 equiv.) was slowly added while maintaining the reaction temperature below 10 °C. After stirring for 5–10 min, dimethyl sulfate (326.3 g, 2.59 mol, 1.1 equiv.) was added while maintaining the reaction temperature below 10 °C (Note: Slow addition is preferred for better regioselectivity). The reaction temperature was then slowly raised to room temperature, and stirring was continued at the same temperature for an additional 2 h. After completion of the reaction (monitored by TLC), the reaction was quenched by the addition of ice-cold water (15.0 L, 30.0 V), and the resulting mixture was stirred at room temperature for 6–8 h. The solid was isolated by filtration and then washed with water (1.5 L, 3.0 V). The wet solid was washed with IPA (1.5 L, 3.0 V) and then with hexane (1.0 L, 2.0 V). Bulk residual water was removed from the solid by maintaining vacuum filtration for 60-90 minutes. The wet solid was dried in a hot air oven at 50 °C for 7-8 hours (until the moisture content was less than 1.0%). The isolated material, 4-chloro-1-methyl-7-nitro-1H-indazol-3-amine (319.0 g, 60% yield), was used in the next step without further purification. 1 H NMR (400 MHz, CDCl3): δ 7.97 (d, J = 8.32 Hz, 1H), 6.97 (d, J = 8.24 Hz, 1H), 4.63 (bs, 2H), 3.96 (s, 3H).

[0106] Step 5: Preparation of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)methanesulfonamide

[0107] [ka]

[0108] (Step 5a) To a solution of 4-chloro-1-methyl-7-nitro-1H-indazol-3-amine (625.0 g, 2.76 mol, 1.0 equiv) in DCM (6.25 L, 10.0 V) at 0-5 °C, triethylamine (TEA) (837.0 g, 8.27 mol, 3.0 equiv) was added, followed by 4-dimethylaminopyridine (DMAP) (20.60 g, 0.165 mol, 0.06 equiv). The reaction was stirred for 5-10 min, then methanesulfonyl chloride (MSCl) (790.0 g, 6.89 mol, 2.5 equiv) was added slowly, maintaining the reaction temperature below 10 °C. The reaction mixture was allowed to warm to room temperature and then stirred for 1.5-2.0 h. After completion of the reaction (monitored by TLC), the mixture was diluted with water (6.25 L, 10.0 V) and then stirred at room temperature for 15 minutes. The organic layer was separated, and the aqueous layer was extracted with DCM (6.25 L, 10.0 V). The combined organic layers were washed with brine (1.25 L, 2.0 V), dried over Na2SO4, and concentrated to give a crude solid. The solid was triturated with hexane (1.25 L, 2.0 V) at room temperature to give the intermediate N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide, which was used directly in the next step.

[0109] (ii) To a stirred solution of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(methylsulfonyl)methanesulfonamide (prepared above) in ethanol (10.5 L, 20.0 V) at room temperature, 5% aqueous NaOH (4.38 L, 7.0 V) was slowly added [Note: Slow addition via a dropping funnel is preferred]. The reaction was stirred at the same temperature for 3 h. After completion of the reaction (monitored by TLC) [sample preparation for TLC analysis: approximately 1.0 mL of the sample was acidified with 2.0 N aqueous HCl to pH 2-3, extracted with ethyl acetate, and the organic layer was analyzed by TLC], the reaction was cooled to 0-5 °C. The pH was adjusted to 2-3 by the addition of 2.0 N aqueous HCl (3.13 L, 5.0 V) while maintaining the reaction temperature below 10 °C [Note: A precipitate formed upon addition of HCl and increased with stirring]. The reaction mixture was allowed to warm to room temperature and then stirred for 1.5–2.0 h. The resulting solid was isolated by filtration and then washed with water (1.25 L, 2.0 V) followed by hexane (1.25 L, 2.0 V). Bulk residual water was removed from the solid by maintaining vacuum filtration for 60–90 min. The wet material was dried in a hot air oven at 50 °C for 6–7 h (until the moisture content was less than 1.0%) to yield the dried product, N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)methanesulfonamide (640.0 g, 76%) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 8.05 (d, J = 8.32 Hz, 1H), 7.32 (bs, 1H), 7.17 (d, J = 8.28 Hz, 1H), 4.15 (s, 3H), 3.45 (s, 3H).

[0110] Step 6: Preparation of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide

[0111] [ka]

[0112] To a solution of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)methanesulfonamide (635.0 g, 2.08 mol, 1.0 equiv.) and 1-(chloromethyl)-4-methoxybenzene (359.0 g, 2.30 mol, 1.1 equiv.) in DMF (6.35 L, 10.0 V) at room temperature, potassium carbonate (374.7 g, 2.70 mol, 1.3 equiv.) was added. The reaction mixture was heated to 80-90 °C and maintained at that temperature for 3 h. After completion of the reaction (monitored by TLC), the mixture was poured into ice-cold water (19.05 L, 30.0 V). [Note: Slow quenching with vigorous stirring is preferred to avoid clumping as the product precipitates.] The resulting solid was isolated by filtration and washed with water (1.90 L, 3.0 V), followed by hexane (1.27 L, 2.0 V). Vacuum filtration was maintained for 60–90 minutes to remove bulk residual water from the solid. The isolated solid was dissolved in ethyl acetate (12.7 L, 20.0 V) and charcoal (63.5 g) was added. The mixture was heated to 60–70°C and then stirred at that temperature for 30–45 minutes. While still hot (40–50°C), the mixture was filtered through a Celite pad, and the Celite pad was then extracted with ethyl acetate (3.17 L, 5.0 V). The combined filtrate was concentrated to dryness under reduced pressure below 50°C. Ethyl acetate (0.635 L, 1.0 V) was added to the solid at room temperature. The resulting solid suspension was stirred for 30 minutes. The solid was isolated by filtration and then washed with hexane (1.27 L, 2.0 V). Residual water was removed from the solid by maintaining vacuum filtration for 45–60 min to give the product N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (705.0 g, 80% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl3): δ 7.99 (d, J = 8.24 Hz, 1H), 7.27 (d, J = 8.68 Hz, 2H), 7.19 (d, J = 8.24 Hz, 1H), 6.80 (d, J = 8.44 Hz, 2H), 4.95-4.76 (m, 2H), 4.17 (s, 3H), 3.76 (s, 3H), 3.01 (s, 3H).

[0113] Step 7: Preparation of N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide

[0114] [ka]

[0115] To a stirred suspension of zinc powder (540.0 g, 8.23 ​​mol, 10.0 equiv.) in a mixture of THF (3.50 L, 10.0 V) and water (7.0 L, 20.0 V) at room temperature, ammonium chloride (NH4Cl) (449.0 g, 8.23 ​​mol, 10.0 equiv.) was added. To the mixture was added a solution of N-(4-chloro-1-methyl-7-nitro-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (350 g, 0.823 mol, 1.0 equiv.) in THF (7.0 L, 20.0 V). The reaction mixture was stirred at room temperature for 3–4 h. After completion of the reaction (monitored by in-process TLC / HPLC), the mixture was diluted with ethyl acetate (3.5 L, 10.0 V) and water (1.12 L, 2.5 V). The mixture was stirred for 15 min. The reaction mixture was filtered through a pad of Celite, washing with ethyl acetate (1.75 L, 5.0 V). The biphasic filtrate was collected and the phases were separated. The aqueous layer was extracted with ethyl acetate (3.50 L, 10.0 V). The combined organic layers were washed with brine (3.50 L, 10 V), dried over Na2SO4, and then concentrated in vacuo to give a crude solid. MTBE (3.25 L, 10 V) was added to the crude product, and the suspension was stirred at room temperature for 30 minutes. The solid was isolated by filtration. Bulk residual water was removed from the solid by maintaining the vacuum filtration for 30-45 minutes. The wet product was dried in a hot air oven (50 °C) for 2 hours to give the title product, N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (276.0 g, 85% yield) as an off-white solid. 1H NMR (400 MHz, CDCl3): δ 7.29-7.26 (m, 2H), 6.86-6.79 (m, 2H), 6.42 (d, J = 7.80 Hz, 1H), 4.99-4.70 (m, 2H), 4.25 (s, 3H), 3.77 (s, 5H), 2.98 (s, 3H).

[0116] Preparation of 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoic acid

[0117] [ka]

[0118] Synthesis scheme

[0119] [ka]

[0120] Step 1: Preparation of methyl 4-bromo-2-nitrobenzoate

[0121] To a stirred solution of 4-bromo-2-nitrobenzoic acid (500 g, 2032 mmol) in methanol (2000 mL) was added sulfuric acid (500 mL, 9381 mmol) at 0 °C. The solution was stirred at 70 °C for 4 hours. The progress of the reaction was monitored by TLC (SiO2, 30% EtOAc / Pet. Rf = 0.3). After completion of the reaction, the reaction mass was cooled to room temperature and then concentrated under reduced pressure to remove methanol. The resulting residue was poured into water (1000 mL) and the pH was adjusted to pH 9 by adding anhydrous sodium carbonate. The mixture was extracted with ethyl acetate (2 × 1000 mL). The combined organics were washed with water (500 mL) and then brine solution (500 mL). The organic layer was dried over anhydrous Na2SO4, filtered, and then concentrated under reduced pressure to give methyl 4-bromo-2-nitrobenzoate (520 g, 94%) as an off-white solid. H-NMR (400 MHz, CDCl) δ = 8.04-7.99 (m, 1H), 7.85-7.78 (m, 1H), 7.66 (d, J = 8.2 Hz, 1H), 3.92 (s, 3H). LCMS Purity = 95.2%. The product was used directly in the next step without further purification.

[0122] Step 2: Preparation of methyl 2-amino-4-bromobenzoate To a stirred solution of zinc powder (704 g, 10.8 mol) in water (2000 mL) under a nitrogen atmosphere at 0 °C, a solution of methyl 4-bromo-2-nitrobenzoate (400 g, 1538 mmol) in tetrahydrofuran (THF) (4000 mL) was slowly added, followed by the slow addition of acetic acid (1057 mL, 18.5 mol). The reaction mixture was stirred at 27 °C for 4 h. The progress of the reaction was monitored by TLC (SiO, 20% EtOAc / Pet. Rf = 0.4). Upon completion, the reaction mixture was filtered through a Celite pad, and the Celite pad was extracted with EtOAc (2000 mL). The combined filtrates were concentrated under reduced pressure. The resulting residue was diluted with water (3000 mL) and extracted with EtOAc (2 × 4000 mL). The combined organics were washed with saturated NaCO solution (2 × 3000 mL) and then brine (2 × 2000 mL). The organic layer was dried over anhydrous NaSO, filtered, and then concentrated under reduced pressure to give methyl 2-amino-4-bromobenzoate (350 g, 94%) as an off-white solid. H-NMR (400 MHz, CDCl) δ = 7.76-7.65 (m, 1H), 6.84 (d, J = 1.9 Hz, 1H), 6.78-6.72 (m, 1H), 5.91-5.63 (m, 2H), 3.86 (s, 3H). LCMS Purity = 95.0%. The product was used directly in the next step without further purification.

[0123] Step 3: Preparation of methyl 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoate

[0124] [ka]

[0125] To a stirred solution of methyl 2-amino-4-bromobenzoate (350 g, 1521 mmol) in 1,4-dioxane (7000 mL) were added bis(pinacol)diborane (522 g, 2054 mmol) and potassium acetate (597 g, 6085 mmol). The reaction mixture was degassed by bubbling N2 gas through it for 10 minutes. To the reaction mixture was added PdCl2(dppf) (78 g, 106 mmol). The mixture was stirred at 90 °C for 4 hours. The progress of the reaction was monitored by TLC. Upon completion of the reaction, the mixture was cooled to room temperature. To the mixture were added 2-chloro-6-(trifluoromethyl)pyridine (359 g, 1978 mmol), tribasic potassium phosphate (1130 g, 5325 mmol), and water (1190 mL). The mixture was degassed by bubbling N2 gas through it for 10 minutes. To the mixture was added PdCl2(dppf) (78 g, 106 mmol). The reaction mixture was stirred at 60 °C for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% EtOAc / Pet. Rf = 0.4). Upon completion, the reaction mixture was filtered through Celite, and the Celite pad was then extracted with ethyl acetate (2000 mL). The combined filtrates were concentrated under reduced pressure to give the crude product (550 g) as a brown liquid. This material was purified by silica gel chromatography eluting with 5–30% EtOAc / Pet. Fractions containing the desired product were pooled and concentrated under reduced pressure. The isolated material was washed with n-pentane (2200 mL), and the solid was collected by filtration and then dried under vacuum to give methyl 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoate (380 g, 83%) as an off-white solid. 1 H NMR (CHLOROFORM-d) δ: 7.99 (d, J=8.3 Hz, 1H), 7.92-7.98 (m, 2H), 7.67 (dd, J=6.9, 1.5 Hz, 1H), 7.49 (d, J=1.5 Hz, 1H), 7.27 (dd, J=8.3, 1.8 Hz, 1H), 5.90 (br s, 2H), 3.93 (s, 3H). LCMS Purity = 98.25%.

[0126] Step 4: Preparation of 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoic acid To a stirred solution of methyl 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoate (650 g, 2194 mmol) in tetrahydrofuran (THF) (5000 mL) and water (2167 mL) under a nitrogen atmosphere at 0° C., lithium hydroxide monohydrate (369 g, 8776 mmol) was added. The reaction mixture was stirred at 70° C. for 16 hours. The progress of the reaction was monitored by TLC (SiO, 50% EtOAc / Pet. Rf=0.4). Upon completion, the reaction mixture was concentrated under reduced pressure, and the resulting residue was then dissolved in water (5000 mL) and acidified to pH 4 by the addition of 3 N HCl (3000 mL). The resulting precipitate was collected by filtration, washed with water (4000 mL) and then with n-hexane (5000 mL), and then dried to give 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoic acid (581 g, 93%) as an off-white solid. H-NMR (400 MHz, DMSO-d) δ = 8.18 (d, J = 4.0 Hz, 2H), 7.92-7.88 (m, 1H), 7.84 (d, J = 8.3 Hz, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.22 (d, J = 8.4, 1.8 Hz, 1H). LCMS Purity = 99.62%.

[0127] Example 1 Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0128] [ka]

[0129] Synthesis scheme

[0130] [ka]

[0131] Step 1: Preparation of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (91 g, 301 mmol) and 2-amino-4-(6-(trifluoromethyl)pyridin-2-yl)benzoic acid (94 g, 332 mmol) in acetonitrile (3.8 L) at 27 °C under a nitrogen atmosphere was added pyridine (0.059 L, 724 mmol). The resulting mixture was cooled to −9 °C for 10 min, and then 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (“T3P,” 50 wt % solution in EtOAc, 0.888 L, 1507 mmol) was added dropwise over 10 min. The solution was stirred at −9 °C under a N atmosphere for 2.1 h. To the solution at −9° C. was added N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (120 g, 301 mmol). The solution was then warmed to −5° C. and maintained at that temperature with stirring for 1 h. The reaction mass was then slowly warmed to 27° C. and then stirred at that temperature for 16 h. The progress of the reaction was monitored by TLC (SiO2, 50% EtOAc / Pet. Rf=0.5). Upon completion, the reaction mixture was concentrated under reduced pressure, and the resulting residue was dissolved in EtOAc (5000 mL) and then washed with 1N NaOH solution (2000 mL) followed by brine (1000 mL). The organic layer was dried over Na2SO4, filtered, and then concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography eluting with 30–35% EtOAc / Pet. Fractions containing the desired product were pooled and concentrated under reduced pressure to give tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (252 g, 88%, off-white solid) as a mixture of homochiral atropisomers (diastereomers).

[0132] Step 2: (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)quinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide To a stirred solution of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (97% pure, 252 g, 264 mmol) in TFA (815 mL, 10.6 mol) was added trifluoromethanesulfonic acid (70.4 mL, 793 mmol) at 27 °C. The solution was stirred under a nitrogen atmosphere for 2 h. The progress of the reaction was monitored by TLC (SiO, 50% EtOAc / Pet. Rf = 0.2). Upon completion, the volatiles were removed under a gentle stream of nitrogen gas. The residue was dissolved in EtOAc (5000 mL) and washed with 1N NaOH solution (2000 mL) followed by brine (1500 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to give the crude product, which was purified by silica gel chromatography eluting with 5–15% MeOH in DCM. Fractions containing the desired product were pooled and concentrated under reduced pressure to give (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)quinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (180 g, 95%, off-white solid) as a mixture of homochiral atropisomers (diastereomers). This material was dissolved in methanol:acetonitrile (40:60, 3000 mL) and then purified by preparative SFC using the following method: Column = (R,R) Welk-01, 30 × 250 mm, 5μ, eluent = CO2:methanol (1:1); flow rate = 90.0 g / min; back pressure = 120.0 bar; detection = 254 nm (UV); stack time = 8.8 min; load per injection = 700 mg. The SFC separation produced two peaks that were collected separately.The major peak (second-eluting peak) was concentrated under reduced pressure to give (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)quinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (100 g, 54%) as an off-white solid. The product is a single stereoisomer. 1H-NMR (400 MHz, DMSO-d6) δ = 8.64-8.55 (m, 2H), 8.44-8.25 (m, 3H), 8.01 (d, J = 7.7 Hz, 1H), 7.42-7.31 (m, 2H), 7.07-6.95 (m, 1H), 6.76 (dd, J = 2.0, 8.5 Hz, 2H), 3.70 (s, 3H), 3.59 (dd, J = 4.8, 8.2 Hz, 1H), 3.35 (br d, J = 4.8 Hz, 1H), 3.17 (d, J = 5.1 Hz, 3H), 2.92-2.83 (m, 1H).LCMS Purity = 99%.

[0133] Step 3: Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide To a stirred solution of (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)quinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (45 g, 63.9 mmol) in DMF (450 mL) at 27 °C was added 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4, 4a,5-Tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (20.26 g, 77 mmol), followed by N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride ("EDC-HCl", 14.70 g, 77 mmol), 1-hydroxybenzotriazole hydrate ("HOBt hydrate", 11.75 g, 77 mmol), and N-methylmorpholine (28.1 mL, 256 mmol) were added. The reaction mass was stirred at 27 °C for 24 hours. The progress of the reaction was monitored by TLC (SiO, 50% EtOAc / Pet. Rf = 0.5). Upon completion, the reaction mass was diluted with ice water (1.5 L), and the resulting precipitate was collected by filtration and then dried under vacuum to give the crude product (59 g) as an off-white solid. This crude product was blended with another batch (61 g) of crude product produced by repeating the procedure on the same scale. The combined crude product (120 g) was purified by silica gel chromatography eluting with 20–40% EtOAc / Pet. Fractions containing the desired product were pooled and concentrated under reduced pressure to yield the purified product. Traces of EtOAc residue were removed by crushing the compound using a mortar and pestle and then placing the fine solid in a 50°C oven for approximately 2 hours.This trituration and heating process was repeated four more times until the EtOAc content was reduced to less than 4000 ppm to give N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (85.7 g, 79%) as an off-white solid. 1H NMR (acetone-d6) δ: 8.60 (t, J=1.0 Hz, 1H), 8.58 (s, 1H), 8.48 (d, J=8.0 Hz, 1H), 8.39 (d, J=0.9 Hz, 2H), 8.32 (t, J=7.9 Hz, 1H), 8.16 (d, J=8.6 Hz, 1H), 7.95-7.99 (m, 1H), 7.49 (d, J=7.7 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 6.86 (tt, J=9.3, 2.3 Hz, 1H), 6.70-6.76 (m, 2H), 6.77 (t, J=54.7 Hz, 1H), 4.93 (td, J=9.0, 4.6 Hz, 1H), 4.63-4.74 (m, 2H), 3.69 (s, 3H), 3.55 (dd, J=14.2, 4.6 Hz, 1H), 3.28 (s, 3H), 3.15 (dd, J=14.2, 9.4 Hz, 1H), 2.42-2.51 (m, 2H), 1.37-1.43 (m, 1H), 0.95-1.00 (m, 1H).LCMS analysis method: Column: Acquity BEH C18, 2.1 × 50 mm, 1.7 μm particles; Solvent A = 0.1% formic acid in water; Solvent B = 0.1% formic acid in acetonitrile; Flow rate = 0.6 mL / min; Gradient {Time point (min) / % B (%) at time point} = 0 / 3, 0.4 / 3, 7.5 / 98, 9.5 / 98, 9.6 / 3, 10 / 3; Column temperature = 35 °C. LCMS results: Retention time = 5.57 min; Observed ion = 949.98 (M+H); LCMS purity = 99.4%.

[0134] Example 1 Nomenclature: The compound of Example 1 prepared above is a homochiral substance containing axial chirality. The axial chirality can be described using the O / M nomenclature detailed in the IUPAC Gold Book (doi:10.1351 / goldbook.A00547). However, currently, the number of software tools capable of generating chemical names containing the P / M nomenclature is limited, and options for converting chemical names into structural representations of molecules using this nomenclature are even more limited. Therefore, for clarity and convenience, some names for Example 1 are provided below.

[0135] The names for Example 1 generated by ChemDraw Professional 16 (without P / M nomenclature) are as follows: N-((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0136] The chemical names for Example 1 generated by JChem for Excel (including P / M nomenclature) are as follows: N-[(1S)-1-[3-(4-chloro-3-methanesulfonamido-1-methyl-1H-indazol-7-yl)-4-oxo-7-[6-(trifluoromethyl)pyridin-2-yl]-3,4-dihydroquinazolin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.0 2 , 4 ]nona-1(6),8-dien-7-yl]acetamide

[0137] The chemical names for Example 1 generated by ChemDraw Professional 16 with manual addition of P / M nomenclature are as follows: N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(6-(trifluoromethyl)pyridin-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0138] Preparation of 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoic acid [ka]

[0139] Synthesis scheme

[0140] [ka]

[0141] Step 1: Preparation of methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Under argon, a mixture of methyl 2-amino-4-bromobenzoate (10 g, 43.5 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (11.04 g, 43.5 mmol), PdCl(dppf) (1.590 g, 2.173 mmol), and potassium acetate (12.80 g, 130 mmol) in 1,4-dioxane (100 mL) was heated at 97 °C for 2 h. The mixture was cooled to room temperature and then diluted with DCM. The organic layer was washed with water and then brine, dried over MgSO, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by silica gel chromatography (330 g column, 5-30% EtOAc:Hex) to give the product, methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (9.2 g, 76%) as a yellow solid. 1 H NMR (500 MHz, CDCl3) δ ppm 7.86 (d, J=8.05 Hz, 1 H), 7.14 (s, 1 H), 7.06 (dd, J=7.90, 1.04 Hz, 1 H), 5.67 (br s, 2 H), 3.89 (s, 3 H), 1.37 (s, 12 H).

[0142] Step 2: Preparation of methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate In a round-bottom flask, methyl 2-amino-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (14.8 g, 53.4 mmol), 2-chloro-4-(difluoromethyl)pyrimidine (8.79 g, 53.4 mmol), PdCl (Xantphos) (2.019 g, 2.67 mmol), and potassium carbonate (22.14 g, 160 mmol) were combined. The flask was sealed with a rubber septum, and 1,4-dioxane (200 mL) and water (50.0 mL) were added to the flask. The flask was then backfilled with argon (evacuated and then backfilled with argon three times). The mixture was stirred at 60 °C for 3.5 hours. The mixture was cooled to room temperature, and the volatile organics were removed under reduced pressure to provide an aqueous mixture. The slurry was taken up in EtOAc (300 mL) and then further diluted with water (400 mL). The mixture was mixed and then filtered through a Celite pad to remove insoluble material. The organic layer was then separated, washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The residue was taken up in a minimal amount of EtOAc (100 mL), then mixed with Celite and concentrated under reduced pressure to give a free-flowing powder. This powder was divided into three equal portions, and each portion was subjected to reverse-phase chromatography (415 g RediSep Gold C18 column) eluting with (95:5 water:MeCN + 0.1% formic acid):(95:5 MeCN:water + 0.1% formic acid) 25:75 to 0:100. Fractions containing the desired product were pooled and partially concentrated under reduced pressure to give an aqueous mixture. The slurry was combined with EtOAc, and the aqueous layer was made slightly basic (pH 8) by adding 5N aqueous NaOH. The mixture was mixed, and then the organic layer was isolated, washed with brine, dried over MgSO4, and concentrated under reduced pressure to give the product, methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate (10.2 g, 68%) as a dark yellow solid.H NMR (500 MHz, CDCl) δ ppm 9.02 (br d, J = 4.77 Hz, 1 H), 8.01 (d, J = 8.34 Hz, 1 H), 7.86 (s, 1 H), 7.76 (br d, J = 8.35 Hz, 1 H), 7.55 (br d, J = 4.77 Hz, 1 H), 6.52 - 6.78 (m, 1 H), 5.88 (br s, 2 H), 3.94 (s, 3 H). LCMS Method G: Retention time = 2.66 min; observed ion = 321.1 (M + MeCN).

[0143] Step 3: Preparation of 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoic acid To a solution of methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate (12 g, 43.0 mmol) in methanol (50 mL) and THF (50.0 mL) was added 5N aqueous sodium hydroxide (25.8 mL, 129 mmol), and the mixture was stirred at 60° C. for 1 hour, at which point LCMS analysis indicated the reaction was complete. The mixture was cooled to room temperature, and then 1 M aqueous HCl (129 mL, 129 mmol) was added to the mixture. To the dark yellow slurry was added EtOAc (250 mL) and water (150 mL), at which point the yellow slurry partially dissolved, the organic layer became cloudy, but the aqueous layer appeared homogeneous. The organic layer was washed with brine. The organic layer remained cloudy. The organic layer was separated and heated until the cloudy mixture became a clear yellow solution. The solution was dried over MgSO.sub.4, filtered, and concentrated under reduced pressure to give the product 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoic acid (11.3 g, 99%) as a yellow solid. 1H NMR (500 MHz, CD3OD) δ ppm 9.06 (d, J = 5.07 Hz, 1 H), 7.96 (d, J = 8.35 Hz, 1 H), 7.93 (d, J = 1.19 Hz, 1 H), 7.67 (dd, J = 8.49, 1.64 Hz, 1 H), 7.64 (d, J = 5.07 Hz, 1 H), 6.66 - 6.91 (m, 1 H). LCMS Method G: Retention time = 2.14 min; observed ion = 307.0 (M + MeCN).

[0144] Alternative preparation of 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoic acid

[0145] [ka]

[0146] Synthesis scheme

[0147] [ka]

[0148] Preparation of methyl 4-bromo-2-nitrobenzoate This compound was prepared on a 200 g scale according to the procedures reported in WO2005037796 and J. Am. Chem. Soc., 2018, 140 (33), 10553-10561.

[0149] Step 1: Preparation of methyl 4-cyano-2-nitrobenzoate To a stirred solution of methyl 4-bromo-2-nitrobenzoate (340 g, 1307 mmol) in DMF (3000 mL) under nitrogen at 27 °C, copper(I) cyanide (234 g, 2615 mmol) was added. The reaction mixture was then stirred at 150 °C for 5 h. The reaction progress was monitored by TLC (SiO, 20% EtOAc / Pet., Rf = 0.6, UV active). Upon completion, the reaction mixture was cooled to 27 °C. The reaction mixture was poured into EtOAc (5000 mL), and the resulting mixture was washed with 5% aqueous ethylenediamine solution (5000 mL) to remove copper salts. The organic solution was then washed with ice-cold water (3 × 3000 mL) and then ice-cold brine (3000 mL). The organic layer was dried over NaSO, filtered, and concentrated under reduced pressure to give methyl 4-cyano-2-nitrobenzoate as a brown solid (280 g, 83%). The product was used directly in the next step without further purification. 1 HNMR (400 MHz, CDCl3) δ = 8.37 (d, J = 1.6 Hz, 1H), 7.97 (dd, J = 7.9, 1.6 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 3.97 (s, 3H). Note: The work-up process was further optimized to avoid the need for filtration. The reaction mixture was poured into EtOAc (5000 mL), and the resulting mixture was washed with 5% aqueous ethylenediamine (5000 mL) to remove copper salts. The organic solution was then washed with ice-cold water (3 x 3000 mL) and then ice-cold brine (3000 mL). The remaining process was the same as above.

[0150] Step 2: Preparation of methyl 4-carbamimidoyl-2-nitrobenzoate hydrochloride Under nitrogen, to a stirred solution of methyl 4-cyano-2-nitrobenzoate (280 g, 1358 mmol) in MeOH (4000 mL) was added sodium methoxide (44.0 g, 815 mmol), and the reaction mixture was stirred at 27 °C for 16 h. Ammonium chloride (72.6 g, 1358 mmol) was added to the reaction mixture, and the reaction mixture was stirred at 27 °C for 18 h. The reaction progress was monitored by TLC (SiO, 80% EtOAc / Pet., Rf = 0.1, UV active). Upon completion, the reaction mixture was filtered, and the filter cake was extracted with 10% MeOH in DCM (3 × 1000 mL). The combined filtrates were concentrated under reduced pressure to give the crude product as a gummy solid. This material was triturated with EtOAc (1000 mL) to give methyl 4-carbamimidoyl-2-nitrobenzoate hydrochloride as a yellow solid (250 g, 56%). The product was used directly in the next step without further purification. 1 H-NMR (400 MHz, DMSO-d6) δ = 9.01 (br s, 3H), 8.50 (d, J = 1.6 Hz, 1H), 8.23 ​​(dd, J = 7.9, 1.6 Hz, 1H), 8.08 (d, J = 7.9 Hz, 1H), 3.91 (s, 3H). LCMS purity = 79%.

[0151] Preparation of (E)-4-ethoxy-1,1-difluorobut-3-en-2-one

[0152] [ka]

[0153] To a stirred solution of 2,2-difluoroacetic anhydride (179 mL, 1436 mmol) in DCM (1250 mL) at 0 °C, a mixture of pyridine (128 mL, 1580 mmol) and ethoxyethene (165 mL, 1724 mmol) was added dropwise over 1 h. The reaction mixture was warmed to 27 °C and then stirred for 12 h. The reaction mixture was quenched by adding ice-cold water (1000 mL). The organic layer was separated, washed with saturated aqueous NaHCO (1000 mL) and then brine (1000 mL), dried over NaSO, and filtered. The filtrate was carefully concentrated under reduced pressure (pressure: ≥ 100 mbar; bath temperature: ≤ 25 °C) to give (E)-4-ethoxy-1,1-difluorobut-3-en-2-one as a brown liquid (180 g, 80%). The crude compound was used directly in the next step without further purification. 1 HNMR (400 MHz, CDCl3) δ = 7.84 (d, J = 12.4 Hz, 1H), 5.89-5.63 (m, 2H), 4.06 (q, J = 7.0 Hz, 2H), 1.39 (t, J = 7.0 Hz, 3H). GC-MS purity = 95%.

[0154] Step 3: Preparation of methyl 4-(4-(difluoromethyl)pyrimidin-2-yl)-2-nitrobenzoate To a stirred solution of methyl 4-carbamimidoyl-2-nitrobenzoate (200 g, 708 mmol) in EtOH (2000 mL) in a 5 L autoclave flask at 27 °C under a nitrogen atmosphere, (E)-4-ethoxy-1,1-difluorobut-3-en-2-one (159 g, 1062 mmol) was added, followed by triethylamine (296 mL, 2124 mmol). The reaction mixture was stirred at 80 °C for 16 h. The reaction progress was monitored by TLC (SiO, 20% EtOAc / Pet., Rf = 0.5, UV active). The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give methyl 4-(4-(difluoromethyl)pyrimidin-2-yl)-2-nitrobenzoate as a brown liquid (220 g, 58%). The product was used directly in the next step without further purification. 1H-NMR (400 MHz, CDCl3) δ = 9.07-9.00 (m, 1H), 8.80 (dd, J = 7.9, 1.6 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.78-7.56 (m, 1H), 7.62 (d, J = 4.8 Hz, 1H), 6.65 (t, J = 54.8 Hz, 1H), 3.96 (s, 3H). HPLC Purity: 58%.

[0155] Step 4: Preparation of methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate To a stirred solution of methyl 4-(4-(difluoromethyl)pyrimidin-2-yl)-2-nitrobenzoate (220 g, 711 mmol) in EtOH (2150 mL) and water (215 mL) at 27 °C, ammonium chloride (190 g, 3557 mmol) was added, followed by iron (199 g, 3557 mmol). The reaction mixture was stirred at 80 °C for 16 h. The reaction progress was monitored by TLC (SiO, 20% EtOAc / Pet., Rf = 0.4, UV active). Upon completion, the reaction mixture was filtered hot through a Celite pad, and the Celite pad was then extracted with EtOAc (4 × 500 mL). The combined filtrates were concentrated under reduced pressure to give methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate as a yellow solid (230 g, 64%). The product was used directly in the next step without further purification. 1 H-NMR (400 MHz, CDCl3) δ = 8.99 (d, J = 4.8 Hz, 1H), 7.98 (d, J = 8.3 Hz, 1H), 7.83 (s, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 4.8 Hz, 1H), 6.61 (t, J = 54.8 Hz, 1H), 3.91 (s, 3H). LCMS purity = 56%.

[0156] Step 5: Preparation of 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoic acid To a stirred solution of methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate (230 g, 461 mmol) in THF (2300 mL), MeOH (575 mL), and water (192 mL) at 27 °C was added LiOH (66.3 g, 2767 mmol). The reaction mixture was stirred at 50 °C for 16 h. The reaction progress was monitored by TLC (SiO, 40% EtOAc / Pet., Rf = 0.1, UV active). Upon completion, the reaction mixture was cooled to 27 °C and then concentrated under reduced pressure. The crude residue was dissolved in water (1000 mL) and washed with EtOAc (2 × 250 mL). The aqueous layer was acidified to pH ∼6 with 1 N aqueous HCl. The precipitated solid was collected by filtration, washed with water (500 mL) and then n-pentane (500 mL), and then dried to give methyl 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoate as a yellow solid (80 g, 63%). 1 H-NMR (400 MHz, DMSO-d6) δ = 9.15 (d, J = 4.8 Hz, 1H), 7.87-7.84 (m, 2H), 7.74 (d, J = 4.8 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 7.06 (t, J = 54.2 Hz, 1H). LCMS purity = 96%.

[0157] Example 2 Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0158] [ka]

[0159] Synthesis scheme

[0160] [ka]

[0161] Step 1: Preparation of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (76 g, 253 mmol) and 2-amino-4-(4-(difluoromethyl)pyrimidin-2-yl)benzoic acid (73.9 g, 279 mmol) in acetonitrile (2.1 L) was added pyridine (0.049 L, 608 mmol), and the reaction mixture was cooled to −5° C. and stirred at the same temperature for 10 minutes. Then, to the reaction mixture at −5° C., T3P (50% solution in EtOAc, 0.754 L, 1266 mmol) was slowly added. The mixture was stirred at −5° C. for 20 minutes, then warmed to 27° C., and stirred for 2 hours. To the reaction mixture, N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (100 g, 253 mmol) was added in one portion at 27 °C, and the mixture was stirred for 18 h. The reaction progress was monitored by TLC (SiO2, 40% EtOAc / Pet., Rf = 0.4, UV active). The reaction mixture was concentrated under reduced pressure to remove acetonitrile, then diluted with EtOAc (1000 mL) and washed with water (2000 mL). The organic layer was separated, washed with saturated aqueous Na2SO3 (3 × 500 mL), then brine (500 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product as a brown gummy liquid. This was purified by column chromatography on silica gel eluting with 30–40% EtOAc / Pet. Fractions containing the desired product were collected and concentrated under reduced pressure to give tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (180 g, 78%, yellow solid) as a mixture of homochiral atropisomers (diastereomers).

[0162] Step 2: Preparation of (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxoquinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide To a stirred solution of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (110 g, 121 mmol) in DCM (500 mL) was added TFA (374 mL, 4849 mmol) and the solution was stirred for 10 minutes under a N atmosphere at 27 °C. Trifluoromethanesulfonic acid (32.3 mL, 364 mmol) was added and the solution was stirred at 27 °C for 1 hour. The progress of the reaction was monitored by TLC (SiO, 50% EtOAc / Pet., Rf = 0.2). Volatiles were removed under a gentle stream of nitrogen gas. The resulting residue was dissolved in EtOAc (1500 mL) and then washed with 1 M aqueous NaOH (2 × 750 mL) and then brine (750 mL), dried over NaSO, filtered, and concentrated under reduced pressure to give the crude product as an off-white solid. This material was purified by silica gel chromatography eluting with 80–98% EtOAc / Pet. Fractions containing the desired product were collected and concentrated under reduced pressure to give (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxoquinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide as a yellow solid (65 g, 74%). The product was a mixture of homochiral atropisomers (diastereomers). The above procedure was repeated four more times to give a total of 310 g of (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxoquinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide, which was dissolved in DCM:MeCN (30:70, 3055 mL).It was then purified by preparative SFC using the following method: column = (R,R) Welk-01, 30 × 250 mm, 5 μm, eluent = CO2:methanol (1:1); flow rate = 90.0 g / min; back pressure = 120.0 bar; detection = 254 nm (UV); stack time = 16.0 min; load per injection = 800 mg. Separation produced two peaks. The major peak (second to elute) was collected and concentrated under reduced pressure to give (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxoquinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide as a yellow solid (170 g, 51%). The product is a single stereoisomer. 1 H NMR (400 MHz, CDCl3) δ = 9.16-9.07 (m, 1H), 9.01-8.95 (m, 1H), 8.71-8.62 (m, 1H), 8.46-8.37 (m, 1H), 7.68-7.61 (m, 1H), 7.11 (d, J = 7.8 Hz, 1H), 6.86-6.55 (m, 2H), 6.54-6.45 (m, 3H), 3.79-3.74 (m, 3H), 3.71-3.63 (m, 1H), 3.44-3.33 (m, 4H), 2.94-2.83 (m, 1H). LCMS Purity = 94%.

[0163] Step 3: Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide At 27°C, (S)-N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxoquinazolin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (50 g, 61.9 mmol), 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro- To a solution of 1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (16.34 g, 61.9 mmol) and 1-hydroxybenzotriazole hydrate (“HOBt hydrate”, 3.79 g, 24.74 mmol) in DMF (500 mL) was added N-methylmorpholine (13.60 mL, 124 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (21.34 g, 111 mmol). The reaction mixture was stirred at 27° C. for 16 h. The reaction progress was monitored by TLC (SiO, 50% EtOAc / Pet., Rf=0.5, UV active). The reaction mixture was diluted with ice-cold water (7 L) and then stirred for 30 min. The precipitated solid was collected by filtration and then dried under vacuum to give the crude compound as an off-white solid (75 g). LCMS purity = 60%. The above procedure was repeated three more times to give a total of 185 g of crude N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which was blended and then purified by silica gel chromatography eluting with 30-40% EtOAc / Pet. The fractions containing the desired product were collected and concentrated under reduced pressure to give the desired product as an off-white solid (100 g, LCMS purity: 97%).This material was suspended in isopropanol (1000 mL, 10V) and heated at 70° C. for 30 minutes, then slowly cooled to 27° C. over 16 hours to give a crystalline product. The resulting solid was collected by filtration and then dried under vacuum to give N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide as an off-white solid (80 g, 79%).1H NMR (acetone-d6) δ: 9.27 (d, J=5.1 Hz, 1H), 8.89 (d, J=1.8 Hz, 1H), 8.69 (dd, J=8.3, 1.8 Hz, 1H), 8.57 (br s, 1H), 8.39 (d, J=8.3 Hz, 1H), 8.12 (d, J=8.9 Hz, 1H), 7.84 (d, J=5.1 Hz, 1H), 7.51 (d, J=7.7 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 7.03 (t, J=54.4 Hz, 1H), 6.86 (tt, J=9.2, 2.4 Hz, 1H), 6.70-6.76 (m, 2H), 6.78 (t, J=54.7 Hz, 1H), 4.93 (td, J=9.0, 4.6 Hz, 1H), 4.65-4.76 (m, 2H), 3.69 (s, 3H), 3.56 (dd, J=14.2, 4.6 Hz, 1H), 3.27 (s, 3H), 3.15 (dd, J=14.3, 9.2 Hz, 1H), 2.42-2.53 (m, 2H), 1.37-1.44 (m, 1H), 0.95-1.00 (m, 1H).LCMS method: Column = Acquity BEH C18, 2.1×50mm, 1.7μm Particles; Solvent A = 0.1% formic acid in water; Solvent B = 0.1% formic acid in acetonitrile; Flow rate = 0.6 mL / min; Gradient {Time point (min) / % B (%) at time point} = 0 / 3, 0.4 / 3, 3.2 / 98, 3.8 / 98, 4.2 / 3, 4.5 / 3; Column temperature = 35 °C. LCMS results: Retention time = 2.73 min; Observed ion = 933.09 (M+H); Purity = 99%.

[0164] Example 2 Nomenclature: The compound of Example 2 prepared above is a homochiral substance containing axial chirality. The axial chirality can be described using the O / M nomenclature detailed in the IUPAC Gold Book (doi:10.1351 / goldbook.A00547). However, currently, the number of software tools capable of generating chemical names containing the P / M nomenclature is limited, and options for converting chemical names into structural representations of molecules using this nomenclature are even more limited. Therefore, for clarity and convenience, some names for Example 2 are provided below.

[0165] The names for Example 2 generated by ChemDraw Professional 16 (without P / M nomenclature) are as follows: N-((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0166] The chemical names for Example 2 generated by JChem for Excel (including P / M nomenclature) are as follows: N-[(1S)-1-[(3P)-3-(4-chloro-3-methanesulfonamido-1-methyl-1H-indazol-7-yl)-7-[4-(difluoromethyl)pyrimidin-2-yl]-4-oxo-3,4-dihydroquinazolin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.0 2 , 4 ]nona-1(6),8-dien-7-yl]acetamide

[0167] The chemical names for Example 2 generated by ChemDraw Professional 16 with manual addition of P / M nomenclature are as follows: N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(4-(difluoromethyl)pyrimidin-2-yl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0168] Preparation of 3,3-difluorobutan-1-ol

[0169] [ka]

[0170] Synthesis scheme [ka]

[0171] Step 1: Preparation of 3-oxobutyl benzoate

[0172] [ka]

[0173] To a stirred solution of benzoyl chloride (0.396 L, 3405 mmol) in DCM (1 L) was added pyridine (470 mL) dropwise over 1 h at −70° C. under a nitrogen atmosphere. After stirring at the same temperature for 30 min, a solution of 4-hydroxybutan-2-one (250.0 g, 2837 mmol) in DCM (500 mL) was added dropwise over 1 h. The reaction mixture was warmed to 26° C. and then stirred for 16 h. The reaction progress was monitored by TLC (SiO, 30% EtOAc / Pet. Rf=0.4). Upon completion, the reaction mixture was washed with water (2×1000 mL), 1 N HCl (2×500 mL), and then saturated NaHCO solution (2×500 mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure to give 3-oxobutylbenzoate as a pale yellow liquid (400 g, yield=69%). 1 H NMR (400 MHz, CHLOROFORM-d) δ = 8.05 - 7.94 (m, 2H), 7.60 - 7.51 (m, 1H), 7.47 - 7.36 (m, 2H), 4.65 - 4.54 (t, 2H), 2.97 - 2.84 (t, 2H), 2.28 - 2.13 (s, 3H). HPLC purity = 94.1%.

[0174] Step 2: Preparation of 3,3-difluorobutyl benzoate

[0175] [ka]

[0176] DAST (677 mL, 5125 mmol) was added dropwise over 1 h to a stirred solution of 3-oxobutylbenzoate (90 g, 427 mmol) in dichloromethane (700 mL) under a nitrogen atmosphere at 0° C. The reaction mixture was warmed to 26° C. and stirred for 16 h. The progress of the reaction was monitored by TLC (SiO2, 20% EtOAc / Pet. Rf = 0.6). Upon completion, the reaction mixture was diluted with DCM (500 mL) and slowly poured into cold saturated aqueous NaHCO3 (1 L). The organic layer was separated, washed with brine solution (400 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude compound (95 g) as a yellow liquid. This material was purified by column chromatography using silica gel (100-200 mesh) eluted with 0-5% EtOAc in pet. The product-containing fractions were collected and concentrated under reduced pressure to give 3,3-difluorobutyl benzoate (60 g, yield = 59%) as a brown liquid. 1 H NMR (400 MHz, CDCl3) δ = 8.06 - 8.01 (m, 2H), 7.60 - 7.54 (m, 1H), 7.48 - 7.40 (m, 2H), 4.54 - 4.48 (t, 2H), 2.43 - 2.29 (m, 2H), 1.77 - 1.64 (m, 3H). LCMS purity = 89.74%; m / z = 215.33.

[0177] Step 3: Preparation of 3,3-difluorobutan-1-ol

[0178] [ka]

[0179] To a stirred solution of 3,3-difluorobutyl benzoate (100 g, 467 mmol) in THF (800 mL) at 0 °C under a nitrogen atmosphere, a solution of lithium hydroxide monohydrate (137 g, 3268 mmol) in water (800 mL) was added. The reaction mixture was warmed to 26 °C and then stirred for 16 h. The reaction progress was monitored by TLC (SiO, 20% EtOAc / Pet. Rf = 0.6, KMnO active). Upon completion, the reaction mixture was diluted with diethyl ether (400 mL). The organic layer was separated, and the aqueous layer was re-extracted with diethyl ether (300 mL). The combined organics were washed with brine (200 mL), dried over NaSO, filtered, and concentrated under reduced pressure (volatile products, bath temperature = 25 °C) to give the crude compound as a black liquid. This material was diluted with diethyl ether (100 mL) and treated with charcoal. The mixture was filtered through a pad of Celite. The Celite pad was extracted with diethyl ether (200 mL). The combined filtrate was concentrated under reduced pressure (volatile products, bath temperature = 25 °C) to give 3,3-difluorobutan-1-ol (40 g, yield = 71%) as a pale yellow liquid. 1 H-NMR (400 MHz, CDCl3) δ = 3.87 (t, J = 6.1 Hz, 2H), 2.22 - 2.07 (m, 2H), 1.73 - 1.57 (m, 3H). GCMS Purity = 91.3%; m / z = 110.0.

[0180] Preparation of 2-amino-6-(benzyloxy)nicotinic acid [ka]

[0181] Synthesis scheme [ka]

[0182] Step 1: Preparation of 2-amino-6-(benzyloxy)nicotinic acid

[0183] [ka]

[0184] To a stirred solution of 2-amino-6-chloronicotinic acid (200 g, 1159 mmol) in benzyl alcohol (1400 mL, 13464 mmol) under a N atmosphere at 26 °C, potassium tert-butoxide (390 g, 3477 mmol) was added. The reaction mixture was heated to 120 °C and stirred at that temperature for 16 h. The reaction progress was monitored by TLC (SiO, 10% MeOH in DCM, Rf = 0.5). Upon completion, the reaction mixture was diluted with water (3 L) and extracted with diethyl ether (2 × 1000 mL). The organic layer was separated, and the aqueous layer was acidified to pH 4 using aqueous citric acid (0.5 M). The precipitated solid was collected by filtration and then dried under reduced pressure to give 2-amino-6-(benzyloxy)nicotinic acid (220 g, yield = 72%) as an off-white solid. 1 H NMR (400 MHz, DMSO-d6) δ = 12.56 - 12.32 (m, 1H), 7.97 - 7.91 (m, 1H), 7.52 - 7.41 (m, 2H), 7.38 - 7.11 (m, 5H), 6.03 (d, J = 8.5 Hz, 1H), 5.39 - 5.31 (m, 2H). LCMS Purity = 93%; m / z = 245.29 (M+H).

[0185] Step 2: Preparation of methyl 2-amino-6-(benzyloxy)nicotinate

[0186] [ka]

[0187] To a stirred solution of 2-amino-6-(benzyloxy)nicotinic acid (220 g, 901 mmol) in DMF (2.5 L) at 26 °C under a N atmosphere, potassium carbonate (373 g, 2702 mmol) and iodomethane (0.282 L, 4504 mmol) were slowly added. The reaction mixture was stirred at 27 °C for 16 h. The progress of the reaction was monitored by TLC (SiO, 40% EtOAc / Pet., Rf = 0.6). Upon completion, the reaction mixture was diluted with water (5 L). The precipitated solid was isolated by filtration and then dried under vacuum to give methyl 2-amino-6-(benzyloxy)nicotinate (220 g, yield = 92%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ = 8.00 (d, J = 8.4 Hz, 1H), 7.42-7.40 (m, 2H), 7.39-7.35 (m, 2H), 7.34-7.31 (m, 1H), 6.01 (d, J = 8.4 Hz, 1H), 5.33 (s, 2H), 3.84 (s, 3H). LCMS Purity = 97%, m / z = 259.30 (M+H).

[0188] Step 3: Preparation of methyl 2-amino-6-hydroxynicotinate

[0189] [ka]

[0190] To a stirred solution of methyl 2-amino-6-(benzyloxy)nicotinate (50 g, 190 mmol) in DCM (500 mL) was slowly added TFA (800 mL) and trifluoromethanesulfonic acid (25 mL, 282 mmol) under a N atmosphere at 26 °C. The reaction mixture was stirred at 26 °C for 16 h. The progress of the reaction was monitored by TLC (SiO, EtOAc, Rf = 0.2). Upon completion, the volatiles were removed in vacuo to give the crude product. This material was triturated with diethyl ether (3 × 1000 mL), and the precipitated solid was isolated by filtration. Water (2 L) was added to the solid, and the mixture was stirred for 5 h. The solid was collected by filtration and washed with water. The solid was dried under vacuum to give methyl 2-amino-6-hydroxynicotinate (25 g, yield = 78%) as an off-white solid. 1H NMR (300 MHz, DMSO-d6) δ = 10.92-10.76 (m, 1H), 7.65 (d, J = 9.5 Hz, 1H), 7.43-6.87 (m, 2H), 5.51 (d, J = 9.5 Hz, 1H), 3.69 (s, 3H). LCMS Purity = 99.32%; m / z = 169.32 (M+H). The absence of TFA and trifluoromethanesulfonic acid in the product was confirmed by LCMS analysis. 19 Confirmed by F-NMR. The product was used directly in the next step without further purification.

[0191] Step 4: Preparation of methyl 2-amino-6-(3,3-difluorobutoxy)nicotinate

[0192] [ka]

[0193] To a stirred solution of methyl 2-amino-6-hydroxynicotinate (25 g, 147 mmol) in THF (375 mL) under a N atmosphere at 0° C., triphenylphosphine (77 g, 294 mmol) was added, followed by dropwise addition of DIAD (57.2 mL, 294 mmol). The reaction mixture was stirred at 0° C. for 15 minutes, and then a solution of 3,3-difluorobutan-1-ol (25.3 g, 221 mmol) in THF (125 mL) was added dropwise at 0° C. The reaction mixture was allowed to warm to 27° C. and then stirred for 5 hours. The reaction progress was monitored by TLC (SiO, EtOAc, Rf = 0.5). Upon completion, the reaction mixture was concentrated under reduced pressure to give the crude product. This material was stirred in MTBE:PET (1:1, 1 L). The mixture was filtered, and the filter pad was extracted with MTBE:PET (1:1, 4 × 200 mL). The combined filtrate was concentrated under reduced pressure to give a pale yellow gummy solid. This material was purified by column chromatography using silica gel (100-200 mesh) and eluted with 10-20% EtOAc in pet. The product-containing fractions were collected and concentrated under reduced pressure to give methyl 2-amino-6-(3,3-difluorobutoxy)nicotinate (20 g, yield = 48%) as a pale yellow liquid. 1 H NMR (400 MHz, CDCl3) δ = 8.05 - 7.95 (m, 1H), 6.02 (d, J = 8.8 Hz, 1H), 4.45 (t, J = 6.8 Hz, 2H), 3.80 (s, 3H), 2.40 - 2.22 (m, 2H), 1.68 (t, J = 18.6 Hz, 3H). LCMS purity = 91.1%, m / z = 261.25 (M+H).

[0194] Step 5: Preparation of 2-amino-6-(3,3-difluorobutoxy)nicotinic acid

[0195] [ka]

[0196] To a stirred solution of methyl 2-amino-6-(3,3-difluorobutoxy)nicotinate (5.7 g, 20.81 mmol) in THF (120 mL) and methanol (30 mL) at 26 °C, a solution of LiOH (2.491 g, 104 mmol) in water (30 mL) was added. The reaction mixture was heated to 70 °C and stirred at that temperature for 16 h. The progress of the reaction was monitored by TLC (SiO, 50% EtOAc / Pet Rf = 0.2). Upon completion, the reaction mixture was concentrated under reduced pressure. The resulting residue was dissolved in water (60 mL) and acidified to pH 4 using 1 N HCl. The mixture was extracted with ethyl acetate (3 × 100 mL). The combined organics were washed with brine (100 mL), dried over anhydrous Na.sub.2SO.sub.4 and concentrated under reduced pressure to give 2-amino-6-(3,3-difluorobutoxy)nicotinic acid (4.6 g, yield=87%) as a brown solid. 1 H NMR (400 MHz, CDCl3) δ = 11.66 - 10.84 (m, 1H), 8.12 - 7.97 (m, 1H), 6.07 (d, J = 8.3 Hz, 1H), 4.52 - 4.36 (m, 2H), 2.41 - 2.28 (m, 2H), 1.68 (t, J = 18.6 Hz, 3H). LCMS Purity = 97.68%, m / z = 247.24 (M+H).

[0197] Example 3 Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0198] [ka]

[0199] Synthesis scheme [ka]

[0200] Step 1: Preparation of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate

[0201] [ka]

[0202] To a stirred solution of (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (50 g, 166 mmol) and 2-amino-6-(3,3-difluorobutoxy)nicotinic acid (41.3 g, 166 mmol) in acetonitrile (1000 mL) was added pyridine (47.0 mL, 581 mmol) under a N atmosphere at −25° C. To the resulting mixture was added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (“T3P,” 50 wt % solution in EtOAc, 494 mL, 830 mmol) dropwise over 15 minutes. The solution was warmed to 13° C. and then stirred for 5 hours. To the solution at 13° C. was added N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (62.3 g, 158 mmol). The reaction mass was then slowly warmed to 27° C. and then stirred at that temperature for 48 hours. The progress of the reaction was monitored by TLC (SiO2, 50% EtOAc / Pet., Rf=0.4). Upon completion, the reaction mixture was concentrated under reduced pressure, and the residue was added dropwise to saturated aqueous NaHCO3 solution (1000 mL) at 0° C. A white precipitate formed, which was collected by vacuum filtration. The isolated solid was washed with water (2 L). The vacuum filtration was maintained until most of the remaining water was removed from the solid. The solid was then dissolved in DCM (2 L). The solution was dried over Na2SO4, filtered, and then concentrated under reduced pressure to give the crude product. This material was purified by silica gel chromatography, eluting with 50-65% EtOAc in Pet. Fractions containing the desired product were pooled and concentrated under reduced pressure to give tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (50 g, yield = 31%) as a yellow foamy solid. The above procedure was repeated seven more times on the same scale to produce a total of 592 g of product. The combined product (592 g) was dissolved in MeOH (1 L).The solution was diluted with n-hexane (6 L). An off-white solid precipitated, and the suspension was then stirred for 20 minutes. The solid was collected by vacuum filtration, while retaining the filtrate. The solid was dried under vacuum to give tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (300 g, yield=48%) as an off-white solid. This product is a mixture of homochiral atropisomers (diastereomers). LCMS analytical method: Column = X Bridge BEH C18 (50 mm × 4.6 mm, 2.5 μm particles); Mobile phase A = 5 mM ammonium bicarbonate; Mobile phase B = acetonitrile; Gradient profile (time (min) / %B) = 0 / 5, 0.5 / 5, 1.5 / 15, 7 / 98, 9 / 98, 9.5 / 5, 10 / 5; Column temperature = 35 °C; Flow rate = 1.3 mL / min. LCMS result: Retention time = 6.20 min. Observed ion = 888.09 (M+H); LCMS purity = 95%. Note: The saved filtrate was concentrated and dried under vacuum to give the product (120 g, pale yellow solid), which was also used separately from the product above in downstream chemistry.

[0203] Step 2: Preparation of (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(3,3-difluorobutoxy)-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide

[0204] [ka]

[0205] To a stirred solution of tert-butyl (S)-(1-(3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (95% pure, 300 g, 321 mmol) in DCM (3000 mL) was added trifluoroacetic acid (TFA) (900 mL) followed by trifluoromethanesulfonic acid (158 mL, 1782 mmol) at 0° C. The solution was warmed to 27° C. and then stirred under a nitrogen atmosphere for 2 hours. The progress of the reaction was monitored by TLC (SiO, 80% EtOAc / Pet. Rf=0.3). Upon completion, the volatiles were removed under a gentle stream of nitrogen gas. The residue was added to saturated NaHCO3 solution (1000 mL) at 0 °C. The pH of the solution was adjusted to approximately 8 by adding solid NaHCO3. The mixture was extracted with EtOAc (5 x 1000 mL). The combined organic layers were dried over Na2SO4, filtered, and then concentrated under reduced pressure to give the crude product. This material was purified by silica gel chromatography eluting with 5-10% MeOH in DCM. Fractions containing the desired product were pooled and concentrated under reduced pressure to give (S)—N-(7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(3,3)-difluorobutoxy)-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (211 g, brown foamy solid) as a mixture of homochiral atropisomers (diastereomers, major: 79%, minor: 10% by LCMS). This material was dissolved in methanol:acetonitrile (80:20, 1800 mL) and purified by preparative SFC using the following method: column = (R,R) WHELK-01 (30 × 250 mm, 5 μm particles), eluent = CO:MeOH (60:40); flow rate = 90 g / min; back pressure = 100 bar; detection = 214 nm (UV); stack time = 15.5 min; input amount per injection = 1.125 grams.The pure major peak was collected and concentrated under reduced pressure to give (S)—N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(3,3-difluorobutoxy)-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (151 g, yield=69%) as a brown solid. The product is a single stereoisomer. 1H-NMR (400 MHz, DMSO-d6) δ: 8.41 (d, J = 8.8 Hz, 1H), 7.39 (dd, J = 22.4, 7.9 Hz, 2H), 7.05 (d, J = 8.3 Hz, 1H), 7.03-6.98 (m, 1H), 6.72 (d, J = 8.8 Hz, 2H), 4.66-4.63 (m, 2H), 3.67 (s, 3H), 3.54-3.50 (m, 1H), 3.28-3.23 (m, 1H), 3.21 (s, 3H), 2.88-2.82 (m, 1H), 2.56-2.52 (m, 1H), 2.47-2.44 (m, 1H), 1.73 (t, J = 19.0 Hz, 3H); LCMS method: Column = Acquity BEH C18 (50 mm × 2.1 mm, 1.7 μm particles); Mobile phase A = 0.1% formic acid in water; Mobile phase B = 0.1% formic acid in MeCN. Gradient profile (time (min) / %B): 0 / 3, 0.4 / 3, 3.2 / 98, 3.8 / 98, 4.2 / 3, 4.5 / 3; Column temperature = 35 °C; Flow rate: 0.6 mL / min. LCMS results: Retention time = 1.93 min; Observed ion = 668.05 (M+H); HPLC Purity = 98%; Chiral HPLC Purity = 96.9%.

[0206] Step 3: Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0207] [ka]

[0208] To a stirred solution of (S)-N-((6P)-7-(2-(1-amino-2-(3,5-difluorophenyl)ethyl)-7-(3,3-difluorobutoxy)-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl)-4-chloro-1-methyl-1H-indazol-3-yl)methanesulfonamide (50 g, 74.1 mmol) in DMF (500 mL) at 27 °C was added 2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4, 4a,5-Tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (21.75 g, 82 mmol), followed by N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride ("EDC-HCl", 18.47 g, 96 mmol), 1-hydroxybenzotriazole hydrate ("HOBt hydrate", 13.62 g, 89 mmol), and N-methylmorpholine (65.2 mL, 593 mmol) were added. The reaction mass was stirred at 27 °C for 16 hours. The progress of the reaction was monitored by TLC (SiO, 50% EtOAc / Pet., Rf = 0.5). Upon completion, the reaction mass was diluted with ice water (1 L), and the resulting precipitate was collected by filtration and then dried under vacuum to give the crude product (77 g) as an off-white solid. This crude product was blended with two additional batches of crude product produced by repeating the procedure at the same scale. A combined total of 227 g of crude product was purified by silica gel chromatography eluting with 40–50% EtOAc in Pet. Fractions containing the desired product were pooled and concentrated under reduced pressure to yield 180 g of purified product. This purified product was blended with an additional 25 g batch of similarly prepared product.A portion of the purified product (150 g) was further purified batchwise (30 × 5 g) by reverse-phase chromatography using the following method: column = RediSep 275 g, HP C18 (CV 243 mL, 150 mL / min); mobile phase A = water:MeCN:TFA (950:50:1); mobile phase B = water:MeCN:TFA (50:950:1); gradient profile (time (min) / % B) = 3 / 10, 6 / 20, 9 / 30, 12 / 40, 15 / 50, 18 / 60, 42 / 70 (compound begins to elute), 52 / 80, 57 / 100; flow rate 80 mL / min; column temperature = 26 °C; load = 5 g each time). Fractions containing pure product were pooled and concentrated under reduced pressure to remove acetonitrile components. The aqueous solution was made basic by adding saturated NaHCO3 and then extracted with EtOAc (3 x 500 mL). The combined organics were dried over anhydrous Na2SO4 and then filtered. The filtrate was concentrated under reduced pressure to give the desired product (102 g) as an off-white solid. This material was dissolved in EtOAc (200 mL), and the solution was then diluted with n-hexane (1 L). The resulting precipitate was stirred at 27 °C for 2 hours and then collected by filtration. The solid was dried under vacuum. Traces of solvent residue were removed by crushing the compound using a mortar and pestle and then storing the fine solid in an oven at 50 °C for approximately 2 hours. This trituration and heating process was repeated (approximately 4-5 times) until all traces of solvent were removed (analyzed by NMR), affording N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide as an off-white solid (88.7 g, yield = 87%).1H-NMR (DMSO-d6) δ: 9.86 (s, 1H), 9.45 (d, J = 8.3 Hz, 1H), 8.44 (d, J = 8.7 Hz, 1H), 7.77 (d, J = 8.3 Hz, 1H), 7.48 (d, J = 7.4 Hz, 1H), 7.09 (d, J = 8.7 Hz, 2H), 7.07 - 6.77 (m, 1H), 6.65 (d, J = 6.2 Hz, 2H), 4.70 (d, J = 16.7 Hz, 1H), 4.65 (t, J = 6.3 Hz, 2H), 4.55 (d, J = 16.7 Hz, 1H), 4.51 - 4.45 (m, 1H), 3.50 (s, 3H), 3.42 - 3.37 (m, 1H), 3.18 (s, 3H), 3.06 - 3.00 (m, 1H), 2.56 - 2.52 (m, 2H), 2.47 - 2.42 (m, 2H), 1.73 (t, J = 19.2 Hz, 3H), 1.38 - 1.32 (m, 1H), 0.85 - 0.81 (m, 1H); LCMS method: Column = Acquity BEH C18 (50 mm × 2.1 mm, 1.7 μm particles), Mobile phase A = 0.1% formic acid aqueous solution; Mobile phase B = 0.1% formic acid in MeCN solution; Gradient profile (time (min) / %B) = 0 / 3, 0.4 / 3, 7.5 / 98, 9.5 / 98, 9.6 / 3, 10 / 3; Column temperature = 35 °C; Flow rate = 0.6 mL / min. LCMS result: Retention time = 5.05 min; Observed ion = 913.97 (M + H); HPLC purity = 99.5%; Chiral HPLC purity = 99.5%.

[0209] Naming of Example 3: The compound of Example 3 prepared above is a homochiral substance containing axial chirality. The axial chirality can be described using the O / M nomenclature detailed in the IUPAC Gold Book (doi:10.1351 / goldbook.A00547). However, currently, the number of software tools capable of generating chemical names containing the P / M nomenclature is limited, and options for converting chemical names into structural representations of molecules using this nomenclature are even more limited. Therefore, for clarity and convenience, some names for Example 3 are provided below.

[0210] The names for Example 3 generated by ChemDraw Professional 16 (without P / M nomenclature) are as follows: N-((S)-1-(3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0211] The chemical names for Example 3 generated by JChem for Excel (including P / M nomenclature) are as follows: N-[(1S)-1-[(3P)-3-(4-chloro-3-methanesulfonamido-1-methyl-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.0] 2 , 4 ]nona-1(6),8-dien-7-yl]acetamide

[0212] The chemical name for Example 3 generated by ChemDraw Professional 16 with manual addition of P / M nomenclature is as follows: N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-7-(3,3-difluorobutoxy)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0213] Preparation of N-[(6P)-7-{2-[(1S)-1-amino-2-(3,5-difluorophenyl)ethyl]-7-hydroxy-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-3-yl}-4-chloro-1-methyl-1H-indazol-3-yl]-N-[(4-methoxyphenyl)methyl]methanesulfonamide

[0214] Scheme

[0215] [ka]

[0216] Step 1: To a suspension of (S)-2-((tert-butoxycarbonyl)amino)-3-(3,5-difluorophenyl)propanoic acid (5.49 g, 18.23 mmol) and 2-amino-6-(benzyloxy)nicotinic acid (4.45 g, 18.23 mmol) in acetonitrile (92 mL) (yellow solution) at −25° C. was added pyridine (9.83 mL, 122 mmol) followed by 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (“T3P”, 45.2 mL, 76 mmol). The reaction mixture (which became a clear solution after the addition of T3P) was stirred at −25° C. to 10° C. for 4.5 hours, then N-(7-amino-4-chloro-1-methyl-1H-indazol-3-yl)-N-(4-methoxybenzyl)methanesulfonamide (6 g, 15.19 mmol) was added, and the mixture was stirred for 18 hours while warming to room temperature. The reaction mixture was diluted with ethyl acetate and washed with 1 N NaOH, then water, then 0.5 M citric acid, then water, then dried over Na2SO4, and concentrated in vacuo. The resulting residue was purified on silica (330 g RediSep Gold column) using 15 CV of 0–60% ethyl acetate in hexanes, followed by 10 CV of 60% EtOAc. The desired fractions were pooled and concentrated to give tert-butyl N-[(1S)-1-[(3P,3P)-7-(benzyloxy)-3-(4-chloro-3-{N-[(4-methoxyphenyl)methyl]methanesulfonamido}-1-methyl-1H-indazol-7-yl)-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]carbamate (major) and tert-butyl N- A mixture of [(1S)-1-[(3M,3M)-7-(benzyloxy)-3-(4-chloro-3-{N-[(4-methoxyphenyl)methyl]methanesulfonamido}-1-methyl-1H-indazol-7-yl)-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]carbamate (minor) was obtained as a pale yellow solid (8.1 g, 9.14 mmol, 60.1% yield). LC / MS: m / z = 886.25 [M+1]+.

[0217] Step 2: TFA (21.1 mL, 274 mmol) was added to a solution of tert-butyl (S)-(1-(7-(benzyloxy)-3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate (product from Step 1, 8.1 g, 9.14 mmol) in dichloromethane (45.7 mL). The mixture was stirred at room temperature for 2 hours. The resulting pale yellow solution was concentrated. The residue was taken up in ethyl acetate and washed three times with 1N NaOH, then dried over Na2SO4 and concentrated in vacuo to give an oily residue. The residue was purified on silica gel (330 g RediSep Gold column) using a gradient method (solvent A:solvent B 65:35 → 0:100 (2 CV), then 0:100 (9 CV); solvent A = hexane; solvent B = 9:9:2 hexane:ethyl acetate:MeOH). The first-eluting isomer (major) was collected and concentrated in vacuo to give N-[(6P)-7-{2-[(1S)-1-amino-2-(3,5-difluorophenyl)ethyl]-7-hydroxy-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-3-yl}-4-chloro-1-methyl-1H-indazol-3-yl]-N-[(4-methoxyphenyl)methyl]methanesulfonamide (4.1 g, 5.89 mmol, 64.5% yield). 1 H NMR (500 MHz, DMSO-d6) δ 7.86 - 7.98 (m, 1 H) 7.15 - 7.37 (m, 4 H) 6.97 - 7.06 (m, 1 H) 6.70 - 6.89 (m, 4 H) 6.40 - 6.48 (m, 1 H) 4.70 - 4.88 (m, 2 H) 3.41 - 3.81 (m, 7 H) 3.20 - 3.28 (m, 1 H) 3.08 - 3.12 (m, 3 H) 2.71 - 2.79 (m, 1 H) 1.69 - 2.00 (m, 2 H). LC / MS: m / z = 696.20 [M+1] + .

[0218] Preparation of N-((S)-1-((3P)-3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-hydroxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0219]

change

[0220] To a stirred solution of N-[(6P)-7-{2-[(1S)-1-amino-2-(3,5-difluorophenyl)ethyl]-7-hydroxy-4-oxo-3H,4H-pyrido[2,3-d]pyrimidin-3-yl}-4-chloro-1-methyl-1H-indazol-3-yl]-N-[(4-methoxyphenyl)methyl]methanesulfonamide (0.926 g, 1.330 mmol) in DMF (13 mL) was added 2-((3bS,4aR)-3-(difluoromethyl)-5,5- Difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetic acid (0.351 g, 1.330 mmol), 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) ("HATU", 0.531 g, 1.397 mmol), and DIPEA (0.581 mL, 3.33 mmol) were added. The reaction mixture was stirred for 2 hours, then the reaction mixture was diluted with water and extracted with ethyl acetate. The combined EtOAc extracts were washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude product was purified by silica gel flash chromatography using 10 to 100% ethyl acetate in hexanes to give N-((S)-1-((3P)-3-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-hydroxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (1.1 g, 88%) as an off-white foamy solid. LC / MS: m / z = 942.25 [M+1] + .

[0221] Example 4 Preparation of N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7)-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0222] [ka]

[0223] A solution of diisopropyl(E)-diazene-1,2-dicarboxylate ("DIAD", 0.125 mL, 0.637 mmol) in THF (0.2 mL) was added to N-(1-((3P)-3)-(4-chloro-3-(N-(4-methoxybenzyl)methylsulfonamido)-1-methyl-1H-indazol-7-yl)-7-hydroxy-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-( A mixture of (3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (0.2 g, 0.212 mmol), 3,3,3-trifluoropropan-1-ol (0.073 g, 0.637 mmol), and triphenylphosphine (0.178 g, 0.679 mmol) in tetrahydrofuran (2.1 mL) was added dropwise at room temperature. The reaction mixture was stirred at room temperature for 18 h and then concentrated in vacuo. The residue was purified on silica gel (24 g RediSep Gold column) using a 15 CV gradient of 0 to 60% ethyl acetate in hexanes, followed by 5 CV of 60% ethyl acetate in hexanes. Fractions containing pure product were pooled and concentrated to give a yellow solid. This solid was taken up in DCM (1 mL):TFA (0.5 mL), the solution was cooled to 0° C., and to this solution was added trifluoromethanesulfonic acid (0.057 mL, 0.637 mmol). The mixture was stirred for 1 hour and then concentrated in vacuo. The residue was taken up in ethyl acetate, washed with 1 N NaOH, washed with 0.5 M citric acid, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was subjected to silica gel chromatography (24 g RediSep Gold column) using 20 CV of 0-60% ethyl acetate in hexanes, followed by 10 CV of 60% ethyl acetate.Fractions containing pure product were pooled and then concentrated in vacuo to give N-(1-((6P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide (0.078 g, 0.081 mmol, 38.0% yield) as a brown solid. 1 H NMR (500 MHz, METHANOL-d4) δ ppm 8.46 - 8.53 (m, 1 H) 7.28 - 7.34 (m, 1 H) 7.19 - 7.24 (m, 1 H) 7.03 - 7.09 (m, 1 H) 6.53 - 6.81 (m, 4 H) 4.80 (dd, J=5.96, 2.98 Hz, 3 H) 4.49 - 4.62 (m, 2 H) 3.58 - 3.62 (m, 3 H) 3.40 - 3.49 (m, 1 H) 3.22 - 3.24 (m, 3 H) 3.06 - 3.14 (m, 1 H) 2.80 - 2.89 (m, 2H) 2.37 - 2.44 (m, 2H), 1.32 - 1.37 (m, 1H), 0.96 - 1.01 (m, 1H). LCMS analytical method: Column = Acquity UPLC BEH C18, 2.1 x 100 mm, 1.7 μm particles; injection volume = 5.00 μL; flow rate = 0.80 mL / min; Solvent A = 95:5 water:MeCN (with 0.1% v / v formic acid); Solvent B = 5:95 water:MeCN (with 0.1% v / v formic acid); elution profile = Start %B: 0, End %B: 100, gradient time: 3.5 min, followed by a 1 min hold at 100% B; Detector Wavelength 1 = 220 nm, Detector Wavelength 2 = 254 nm. LCMS retention time = 3.097 min; m / z = 918.05 [M+1]. + .

[0224] The compound of Example 3 prepared above is a homochiral substance containing axial chirality. The axial chirality can be described using the O / M nomenclature detailed in the IUPAC Gold Book (doi:10.1351 / goldbook.A00547). However, currently, the number of software tools capable of generating chemical names containing the P / M nomenclature is limited, and options for converting chemical names into structural representations of molecules using this nomenclature are even more limited. Therefore, for clarity and convenience, some names for Example 3 are provided below.

[0225] The names for Example 3 generated by ChemDraw Professional 16 (without P / M nomenclature) are as follows: N-((S)-1-(-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7)-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0226] The chemical names for Example 3 generated by JChem for Excel (including P / M nomenclature) are as follows: N-[(1S)-1-[(3P,3P)-3-(4-chloro-3-methanesulfonamido-1-methyl-1H-indazol-7-yl)-4-oxo-7-(3,3,3-trifluoropropoxy)-3H,4H-pyrido[2,3-d]pyrimidin-2-yl]-2-(3,5-difluorophenyl)ethyl]-2-[(2S,4R)-9-(difluoromethyl)-5,5-difluoro-7,8-diazatricyclo[4.3.0.0] 2 , 4 ]nona-1(6),8-dien-7-yl]acetamide

[0227] The chemical name for Example 3 generated by ChemDraw Professional 16 with manual addition of P / M nomenclature is as follows: N-((S)-1-((3P)-3-(4-chloro-1-methyl-3-(methylsulfonamido)-1H-indazol-7-yl)-4-oxo-7)-(3,3,3-trifluoropropoxy)-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide

[0228] biological methods HIV cell culture assay MT-2 cells, 293T cells, and NL 4-3 Proviral DNA clones of the virus were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 mg / mL penicillin G, and up to 100 units / mL streptomycin. 293T cells were grown in DMEM medium supplemented with 10% heat-inactivated FBS, 100 mg / mL penicillin G, and up to 100 mg / mL streptomycin. Recombinant NL, in which a portion of the nef gene was replaced with the Renilla luciferase gene, was used. 4-3 The proviral clone was used to generate the reference virus used in these studies. Recombinant NL was transfected into 293T cells using Transit-293 transfection reagent from Mirus Bio LLC (Madison, WI). 4-3Recombinant virus was prepared by transfection of the proviral clone. Supernatants were collected after 2–3 days, and the amount of virus present was titrated in MT-2 cells by measuring luciferase enzyme activity as a marker. Luciferase was quantified using EnduRen Live Cell Substrate from Promega (Madison, WI). The antiviral activity of compounds against the recombinant virus was quantified by measuring luciferase activity in MT-2 cells infected with the recombinant virus for 4–5 days in the presence of serially diluted compounds.

[0229] (Fa)=1 / [1+(ED 50 The median effective concentration (EC 50 ) was calculated (Johnson VA, Byington RT. Infectivity Assay. In Techniques in HIV Research. ed. Aldovini A, Walker BD. 71-76. New York: Stockton Press. 1990). Percent inhibition = 1 / [1 + (EC 50 The 50% inhibitory concentration (EC ) was calculated by using the exponential form of the median effect equation: [( ... 50 ) was calculated.

[0230] Compound cytotoxicity and corresponding CC 50 Values ​​were determined using the same protocol as described for the antiviral assay, except that uninfected cells were used. Cytotoxicity was assessed on day 4 in uninfected MT-2 cells by using a colorimetric assay based on XTT (2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) (Sigma-Aldrich, St Louis, MO).

[0231] [Table 1]

[0232] Measurement procedure for pharmacokinetic parameters in subcutaneous in vivo experiments (Formulation A) To a 20 mL vial containing Example 1 (320 mg) was added PEG300 (0.906 mL). The mixture was sonicated to obtain a clear solution. Water (0.160 mL) was added to this solution to obtain a slightly cloudy solution. The mixture was sonicated for 5 minutes to obtain a clear solution. The resulting solution was "Formulation A," and the solution had the following concentrations: 21.3 w / w% Example 1, 68.1 w / w% PEG300, and 10.6 w / w% water.

[0233] Formulation A was administered subcutaneously to Wistar Hansen rats at a dose of 0.167 mL / kg. Blood samples were collected at 0.5, 1, 3, 5, 7, 24, 48, and 72 hours after administration and at 6, 8, 12, 15, 19, 22, 26, 29, 33, 36, 40, 43, 47, 50, 54, 57, and 61 days. Blood samples were collected in K2EDTA tubes and centrifuged at 1500–2000 × g to obtain plasma. Plasma samples were stored at -80°C until analysis by LC-MS / MS. All in vitro samples were injected into an MDS Sciex API 4000 triple quadrupole LC-MS / MS system. The analytical column used was a Phenomenex Kinetex® 2.6 μm PS (C18, 2.1 mm × 50 mm, 2.6 μm) maintained at room temperature. Mobile phase A consisted of 0.1% (v / v) formic acid in MilliQ purified water. Mobile phase B consisted of 0.1% (v / v) formic acid in acetonitrile. The flow rate was 0.70 mL / min. The gradient consisted of mobile phase B held at 35% for 0.5 min, then linearly increasing from 35% to 98% over 1.5 min, holding at 98% for 0.5 min, and holding at 35% for 0.5 min. The results of the PK experiment are shown in Table 1 and Figure 1.

[0234] [Table 2]

[0235] The present disclosure is not limited to the exemplary embodiments described above, which are to be considered in all respects as illustrative and not restrictive, and reference should be made to the appended claims rather than to the embodiments described above, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced.

Claims

1. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt thereof and a solvent or diluent, The compound has formula Ia, Ib, Ic, or Id: 【Chemistry 1】 is a compound of the solvent or diluent comprises polyethylene glycol (PEG) and ethanol; the pharmaceutical composition is a solution; The pharmaceutical composition, wherein the compound of formula Ia, formula Ib, formula Ic or formula Id or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition at a concentration of 50 to 500 mg / mL, based on the weight of the free compound of formula Ia, formula Ib, formula Ic or formula Id.

2. 10. The pharmaceutical composition of claim 1, further comprising an excipient selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, poloxamer 207, poloxamer 338, sodium chloride, and sodium hydroxide.

3. The pharmaceutical composition of claim 2, comprising poloxamer 188.

4. A pharmaceutical composition according to claim 2 or 3, comprising sodium hydroxide.

5. A pharmaceutical composition described in any one of claims 2 to 4, wherein at least 90% by weight of the additive is poloxamer 188.

6. The pharmaceutical composition according to any one of claims 1 to 5, comprising water.

7. The pharmaceutical composition according to any one of claims 1 to 6, wherein the average molecular weight of PEG is about 300 (PEG300).

8. 8. The pharmaceutical composition of any one of claims 1 to 7, wherein at least 90% by weight of the solvent or diluent is water and PEG 300.

9. 9. The pharmaceutical composition of claim 8, wherein the water is present in the pharmaceutical composition at 8 to 20% by weight, and the PEG 300 is present in the pharmaceutical composition at 60 to 85% by weight.

10. 10. The pharmaceutical composition of claim 9, wherein the water is present in the pharmaceutical composition at 8 to 12% by weight and the PEG 300 is present in the pharmaceutical composition at 63 to 70% by weight.

11. 11. The pharmaceutical composition of any one of claims 1 to 10, wherein the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is present in the pharmaceutical composition at a concentration of 225 to 275 mg / mL, based on the weight of the free compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id.

12. 11. The pharmaceutical composition of any one of claims 1 to 10, wherein the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is present in the pharmaceutical composition at a concentration of 275 to 300 mg / mL, based on the weight of the free compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id.

13. 11. The pharmaceutical composition of any one of claims 1 to 10, wherein the compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id, or a pharmaceutically acceptable salt thereof, is present in the pharmaceutical composition at a concentration of 350 to 425 mg / mL, based on the weight of the free compound of Formula Ia, Formula Ib, Formula Ic, or Formula Id.

14. The pharmaceutical composition of claim 1, wherein the compound is a compound of formula Ic or Id.

Images